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1Thesis summary 
Thesis Summary and Aim 
Glycosylation is the enzymatic modification of various compounds with sugars. In the present 
work, glycosylation of proteins and lipids is investigated. To be able to carry out glycosylation 
reactions, the cell relies on an enzymatic machinery to synthesize activated sugars and to 
transport these to the proper place within the cell. Then, enzymes transfer the sugar onto a 
specific acceptor substrate. These enzymes are called glycosyltransferases. The first 
glycosylation reaction may be followed by additional ones, elongating the initial unit to a sugar 
chain.
The aim of my thesis was to characterize members of a family of enzymes from Drosophila
melanogaster that elongate the sugar chains of glycolipids and glycoproteins. Sequence 
homology between these and related enzymes suggested that they all form a E1,3 linkage. The 
fly was chosen as model system to have a basis to later genetically investigate 
glycosyltransferase mutants. 
Mutations in one of the characterized enzymes, a E1,3 glycosyltransferase encoded by brainiac,
are lethal and embryos display an enlarged central nervous system compared to the wild-type
animal. Activity determination and product analysis showed, that the enzyme transfers the sugar 
N-acetylglucosamine onto a mannose in the E configuration. These donor and acceptor 
preferences suggested involvement of the enzyme in the synthesis of the arthro-series core 
structure of insect glycolipids, N-acetylglucosamine E1,3 mannose E1,4 glucose E-ceramide. 
Indeed, in vitro activity towards glycolipids could be established. The arthro-series glycolipid 
core is not found in vertebrates and attempts to complement the brainiac mutant by transgenic 
expression of mammalian enzymes displaying sequence similarities to Brainiac failed. However, 
we were able to correct the mutant phenotype with a sequence-similar Caenorhabditis elegans
transgene, “Bacillus thuringiensis resistance-5” (bre-5). Caenorhabditis elegans mutants for this 
brainiac-orthologous gene have an only slightly reduced viability and fertility but escape the 
lethal effects of being fed a specific bacillus thuringiensis toxin. Bacillus thuringiensis toxins are 
extensively used as a means for pest control in agriculture and are also transgenically expressed 
in wheat, soy bean and corn. In the first place, the rescue of the Drosophila melanogaster 
brainiac mutant by the Caenorhabditis elegans enzyme shows that Bacillus thuringiensis toxins
can bind glycolipids. The binding to the arthro-series core partially explains why animals that do 
not have this glycolipid-core, are not affected by this toxin. Secondly, the difference in resistance 
levels or in the acquisition of resistance to Bacillus thuringiensis toxins by different organisms 
may be explained by the (lack of) vital importance of the receptor-glycolipid for the organism, 
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since Caenorhabditis elegans evidently survives without this arthro-series core, while 
Drosophila melanogaster does not. 
Investigation of E1,3 glycosyltransferases was then extended to a large family of Drosophila 
melanogaster genes comprising nine members. The proteins encoded by these genes displayed 
extensive sequence similarity to the mammalian E1,3 galactosyltransferase enzyme, which 
synthesizes the T-antigen. The T-antigen is the disaccharide galactose E1,3 N-
acetylgalactosamine D-O-Serine/Threonine, which represents the core structure of mucin-protein 
O-glycosylation. The T-antigen is formed by most animals. While mammals harbour only one T-
antigen- synthesizing enzyme, we found four enzymes in Drosophila melanogaster, which show 
the corresponding activity. Transcripts of the most active of these enzymes were found to be 
deposited by the mother into the embryo and later to be expressed in the amnioserosa, a transient 
tissue that vanishes during embryogenesis. The amnioserosa – epidermis interaction is 
considered to be a wound-healing model, because it separates the lateral and the dorsal epidermis 
during early stages of embryonic development, then disappears completely to allow the two 
tissues to coalesce. Transcripts of two other enzymes were found in the salivary glands. The 
developmental and physiological roles of these enzymes in Drosophila melanogaster await the 
characterization of mutant animals. However, the enzymological basis for the genetic analysis of 
the T-antigen was laid with the present work. 
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Zusammenfassung und Ziel 
Unter Glykosylierung versteht man die enzymatische Derivatisierung von verschiedensten 
Verbindungen mit Zuckern. In dieser Arbeit ging es um die Glykosylierung von Proteinen und 
Lipiden. Um glykosylieren zu können, benötigt die Zelle Enyzme und Energie, um aktivierte 
Zucker herzustellen, und um diese an den richtigen Platz in der Zelle zu transportieren. 
Schliesslich braucht es Enzyme, welche die eigentlichen Glykosylierungsreaktionen durchführen. 
Diese Enzyme heissen Glykosyltransferasen. Dem ersten Glykosylierungsschritt folgt bisweilen 
eine Verlängerung zu einer Zuckerkette durch weitere Glykosyltransferasen.
Das Ziel meiner Dissertation war die Charakterisierung einer Familie von Glykosyltransferasen, 
deren Mitglieder die Zuckeranteile von Glykoproteinen und Glykolipiden mit anderen 
Zuckermolekülen in einer E1,3 Bindung verknüpfen. E1,3 Glykosyltransferasen weisen 
untereinander Ähnlichkeiten in ihrer Aminosäurensequenz auf, unabhängig davon, welchen 
Zucker sie auf welchen anderen Zucker transferieren. Um herauszufinden, ob und wie wichtig 
E1,3 verknüpfte Zuckerverbindungen sind, haben wir E1,3 Glykosyltransferasen von Drosophila
melanogaster untersucht, damit später Mutanten auf genetische Interaktionen getestet werden 
können.
Für eines der untersuchten Enzyme gab es bereits Mutanten. Homozygote brainiac - Mutanten 
sterben und weisen als Embryonen ein abnormal vergrössertes zentrales Nervensystem auf. Bei 
der biochemischen Charakterisierung des Enzyms stellte sich heraus, dass die E1,3
Glykosyltransferase Brainiac den Zucker N-Acetylglukosamin auf Mannose in der E
Konfiguration überträgt und dass es an der Herstellung von Arthropoden-Glykosphingolipiden
beteiligt ist, indem es deren Kernstruktur, Mannose E1,4Glukose E-Ceramide, mit N-
Acetylglukosamin elongiert. Tatsächlich konnten wir in vitro Aktivität von Brainiac gegen 
Insekten-Glykolipide nachweisen. Während der Versuch scheiterte, den brainiac-Phänotyp
durch Transgene von sequenz-ähnlichen Säugetier-Enzymen zu korrigieren, gelang dies mit 
Hilfe eines Caenorhabditis elegans Transgens. Die Caenorhabditis elegans Mutanten in diesem 
brainiac-orthologen Gen, bre-5 (bacillus thuringiensis resistance), überleben und sind fertil, 
hingegen sind sie resistent gegen ein Bacillus thuringiensis Toxin. Diese Toxine werden häufig 
zur Bekämpfung von Schadinsekten in der Landwirtschaft eingesetzt und aus demselben Grund 
auch transgen in Mais, Soja, Weizen und Tabak exprimiert. Die transgene Komplementation der 
lethalen Drosophila melanogaster brainiac Mutante durch das Caenorhabditis elegans Enzym 
beweist erstens, dass Bacillus thuringiensis Toxine (Bt-Toxine) Glykolipide binden können, die 
nur in Arthropoden vorkommen. Das erklärt, weshalb Vertebraten keine Schäden durch diese Bt-
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Variante erleiden. Zweitens impliziert dieses Resultat, dass Drosophila melanogaster kaum 
dieselbe Resistenz gegen dieses Toxin entwickeln wird wie Caenorhabditis elegans, da das Bt-
Toxin bindende Glykolipid für die Fliege überlebenswichtig ist.
Die Untersuchung der E1,3 Glykosyltransferasen wurde sodann auf eine Familie von E1,3
Glykosyltransferasen mit neun Mitgliedern ausgedehnt, welche Sequenzähnlichkeiten zu einem 
Säugetierenzym aufweist, welches das T-Antigen herstellt. Das T-Antigen ist das Disaccharid 
Galaktose E1,3 N-Acetylgalaktosamin-Serine/Threonine, welches die Kernstruktur der Mucin- 
Protein O-Glykosylierung darstellt. Das T-Antigen kommt in vielen Tierarten vor. Während es in 
Säugetieren wahrscheinlich nur eine T-transferase gibt, zeigten in Drosophila melanogaster vier 
Isoenzyme die entsprechende Aktivität. Transkripte des aktivsten dieser Enzyme in Drosophila 
melanogaster wurden in der maternalen mRNA und in der Amnioserosa gefunden. Die 
Interaktion zwischen Amnioserosa und Epidermien wird als Wundheilungsmodell betrachtet, 
trennt sie doch während der Embryonalentwicklung zwei Epidermien, die laterale und die 
dorsale, die nach dem Abbau der Amnioserosa zusammenwachsen. Die mRNA zweier anderer 
Enzyme wurde in den Speicheldrüsen des Embryos gefunden. Die Rolle dieser Enzyme in der 
Embryonalentwicklung und Physiologie von Drosophila melanogaster muss erst noch mit Hilfe 
von in vivo Modellen untersucht werden. Mit dieser Arbeit liegen die enzymatischen Grundlagen 
dazu jetzt vor. 
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GLYCANS AND GLYCOSYLTRANSFERASES OF
DROSOPHILA MELANOGASTER
1 Summary
Glycans are the carbohydrate-moiety of glycoproteins and glycolipids. Their function ranges 
from the modulation of specific ligand-receptor interactions to providing stabilizing and barrier 
functions. Of all genes responsible for the formation of glycan chains, glycosyltransferases are 
the foremost targets for the genetic analysis of glycan function since they are usually specific for 
one glycan-type and the linkage produced. One structurally related family of 
glycosyltransferases catalyzes the elongation of glycans with monosaccharides in a E1,3 linkage. 
In Drosophila melanogaster, E1,3 glycosyltransferases have been shown to be implicated in the 
synthesis of glycosphingolipids, proteoglycans, mucin type O-glycans and O-fucose initiated O-
glycosylation of proteins carrying epidermal growth factor receptor (EGFR)-modules. This 
dissertation discusses some principles of biosynthesis, structure and function of glycans in 
Drosophila melanogaster.
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2 Definitions
Glycans are the carbohydrate moiety of glycoproteins or glycosphingolipids, which belong to the 
super-family of glycoconjugates. Glycoconjugates that have lost their glycan chains are called 
aglycones. Glycans contain one to many monosaccharides linked together as oligomers or 
polymers (Figure 1). 
aglycone
glyco-
conjugate
glycan mono-
saccharide
Figure 1: Definitions for glycoconjugate, glycan, aglycone, and monosaccharide.
A glycan is termed “complex” if it contains more than one type of monosaccharides. Complexity 
is no structural feature since a simple glycan like cellulose, consisting solely of glucose, may 
yield highly complex three dimensional structures. 
The common monosaccharide residues in animal glycans are glucose (Glc), galactose (Gal), 
mannose (Man), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), fucose 
(Fuc), xylose (Xyl), glucuronic acid (GlcA), iduronic acid (IdoA) and sialic acid (Sia). Examples 
of linear representations of their chemical formula are shown in Figure 2. Monosaccharides in 
glycans of animals are either pentoses or hexoses and their derivatives. The carbons are 
numbered according to the rules of organic chemistry with C-1 to C-6 (Figure 2). Two 
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monosaccharides are referred to as “epimeric”, if the stereochemistry at a single chiral C-Atom 
differs. For example, Man is the C-2 epimer of Glc, whereas Gal is its C-4 epimer (Figure 2). 
Monosaccharides may derive from N-acetylation at C-2, yielding for example the hexosamines 
GlcNAc and GalNAc, or from oxidation at C-6, producing the uronic acids GlcA and IdoA. 
Dehydroxylation at C-6 yields the deoxyhexose Fuc. For an overview of the many types of sialic 
acids found in animal glycans the reader is referred to (1). The orientation of the hydroxyl group 
at C-5 in hexoses (C-4 in pentoses) defines the absolute D- or L- configuration of the 
monosaccharide. D-monosaccharides predominate in nature. Monosaccharide residues within 
glycans may also contain non-carbohydrate moieties, as for example sulfate groups (-SO4),
phosphoethanolamine (pEtn) and phosphocholine (pCho) covalently linked via an ester bond to a 
free hydroxyl group within monosaccharides. 
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Figure 2: Structures of common monosaccharides in animals. Epimers: Glc and Man are C-2 
epimers to each other while Glc and Gal are C-4 epimers. Modifications: GlcNAc is a derivative of 
Glc which is N-acetylated at C-2, GlcA is a derivative of Glc with its –OH group at C-6 oxidized. 
Fuc is the only L-monosaccharide commonly found in animal glycans and is a 6-deoxyhexose. Xyl is 
the only pentose commonly found in animal glycans. There are more than 30 different derivatives of 
Sia but Neu5Ac is the most common. 
Based on the type of functional group besides the hydroxyl-groups, monosaccharides are 
classified into aldoses (all monosaccharides mentioned above) or ketoses (e.g. fructose). Aldoses 
contain an aldehyde group ( CH=O) whereas ketoses contain a ketone group (-CR=O). 
Important chemical properties of the monosaccharide are mediated by the aldehyde or ketone 
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group. Fore exemple, monosaccharides in solution are not often present as open, but more as 
cyclic forms. This is the consequence of the formation of an intramolecular bond within the 
monosaccharide between its ketone/aldehyde-group and one of its hydroxyl groups, creating a 
four-substituted carbon and thus a new chiral center on the carbon upon cycle formation. This 
type of reaction is chemically referred to as hemiacetal-formation. The new chiral centre defines 
the anomericity of the monosaccharide and is traditionally symbolized with D or E. The 
intramolecular hemiacetal is usually formed with the hydroxyl group at C-5 in hexoses or C-4 in 
pentoses. The anomeric carbon is also engaged in the covalent bond between monosaccharides. 
The covalent bond between two monosaccharides is called the glycosidic linkage or glycosidic 
bond and refers to the oligo- and polysaccharide as the peptide bond does to oligo- and 
polypeptides, or the phosphodiester bond to oligo- and polynucleotides. To form the glycosidic 
bond, the D or E anomeric carbon of the hemiacetal monosaccharide engages in a bond with a 
hydroxyl group of another monosaccharide to form an acetal, protecting the reactive aldehyde or 
ketone group. Thus, the monosaccharide involved in the glycosidic linkages via its anomeric 
carbon loses its reduction potential, while the other monosaccharide engaged in the bond with its 
hydroxyl-group is still in equilibrium with its open form and retains its reducing aldehyde group. 
The glycosidic linkage of a disaccharide is described by the anomericity (D or E) of the 
monosaccharide at the non-reducing end and the number of the carbon to which the reacting 
hydroxyl group of the second monosaccharide is attached. For example, the notation 
“GalE1,3GalNAc” means, that the E anomer of Gal at the non-reducing end is engaged in the 
glycosidic bond with its anomeric carbon while GalNAc is engaged in it with the hydroxyl group 
at C-3. 
OH
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Figure 3: Monosaccharides form rings and glycosidic linkages. Left: Carbons of glucose are 
numbered from C-1 to C-6 starting at the carbon of the aldehyde group. Glucose forms an intra-
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molecular hemiacetal, as the C-1 aldehyde group and the C-5 hydroxyl group react to form a six-
membered ring. Cyclization yields two stereochemically different products with respect to C-1, the 
anomeric carbon. The two anomers of glucose are shown in Haworth projection. Right: Glycosidic 
linkages between two monosaccharides are formed by the hydroxyl group at the anomeric carbon (C-
1) and any free hydroxyl group in the other monosaccharide. Exemplified are a GlcD1,6GlcNAcD
and a GlcE1,3GlcNAcD linkage. 
While the peptide bond only yields two non-equal possibilities to link two amino acids, i.e. either 
Ile-Leu or Leu-Ile, two different hexoses may yield 16 different disaccharides. Chemically, more 
than 1.5x1012 structures could be generated from six hexoses (2). However, only very few of 
these linkages are formed in vivo, because glycans are made by enzymatic synthesis and one 
enzyme usually only catalyzes one linkage. For example, Gal is only found in Dor E1,4 and D or 
E1,3 linkages in animals (while bacteria and fungi also display D and E1,6 linkages) (3). These 
linkages are formed by glycosyltransferases (GTs), or - in a few cases - by glycosylhydrolases 
that perform trans-glycosylation (4). The enzymatic formation of different glycoconjugates is 
called glycosylation.
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3 Glycoconjugate classes 
The process of glycosylation yields different classes of glycoconjugates (Figure 4). In animals, 
glycans can be found attached to ceramide, yielding glycosphingolipids or they are protein-
bound, yielding glycoproteins. The different types of glycans can be recognized by their core 
structures, which are conserved among most animals with small variations, while elongated 
structures may vary between species, cell type, tissue, developmental stage or other determinants. 
GAG
S
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E3
Glycolipidsl li i
Cer Cer
E
E4
E
GPI
anchor
I
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X
D6
D4
D6
D2
O-glycans- l
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D D E E
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t l i / l r
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W
E
N-glycans- l
N
E
E
E
DD
Xyl
GlcN
Fuc
GalNAc
Gal
GlcNAc
Glc
Man
PEtn
6
PI
Figure 4: Core structures of eukaryotic glycans. ER N-glycans are preassembled and attached en
bloc to the amine group of asparagines. Monosaccharides bound via the -OH groups of serines or 
threonines constitute the cores of the different O-glycans, DGalNAc attached O-glycans are also 
called “mucin-type”. In C-glycans, Man is bound to tryptophan via C-2 of the indole ring, the 
glycosaminoglycan (GAG) - core structure is attached to -OH groups of serines but not threonines. 
GPI anchor- glycans are preassembled on phosphoinositol (PI) and then transferred en bloc involving 
a transamidation reaction that results in the cleavage of a signal peptide. The glycan moiety of 
eukaryotic glycosphingolipids is attached to ceramide (Cer). A list with glycan types encompassing 
bacterial and plant glycans can be found in (5). 
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4 Glycan functions
It is difficult to predict the functions mediated by specific glycans or their relative importance to 
the organism a priori since their biological roles “span the spectrum from trivial to crucial for 
development and survival of an organism” (6). Functions of glycans include the mediation of 
structural integrity of glycoconjugates or the modulation of specific recognition events (Table 1). 
The glycan moiety of glycoconjugates is recognized by inter- or intracellular binding partners. 
Proteins, that bind to carbohydrates are called lectins. Lectins can be proteins of many functional 
classes, including receptors, signalling proteins, enzymes and structure-preserving proteins.
Glycans influence the function of a glycoconjugate in ways that are organism-, celltype-, glycan-
type- and glycoconjugate- specific. This may be exemplified by the interaction of the lectins 
calnexin and calreticulin with N-glycans in the ER for the quality control of glycoprotein-folding 
(7). Inhibitors of N-glycan biosynthesis have been successfully used to block the exit of N-
glycosylated hepatitis B virus proteins from the ER to the secretory pathway (8), leading to virus 
aggregates in the ER and substantial decrease of the organism’s viral load. The inhibition of as 
little as 6% of cellular glycoprocessing results in a greater than 99% reduction in the secretion of 
hepatitis B virus (9), indicating a higher sensitivity of virus proteins to N-glycan synthesis 
inhibition.
The importance of a particular glycan may also vary between different animal species. For 
example, absence of the glycosphingolipid GlcNAcE1,3ManE1,4GlcE-ceramide is lethal for 
Drosophila during development while C. elegans survives without this glycosphingolipid [I, II]. 
A main motor in the generation of glycan diversity and function between evolutionary lineages 
seem to be parasite – host interactions. A plethora of bacteria and viruses bind to glycans (Table 
1). The parasite genome evolves towards more specific and stronger binding of host factors and 
escaping its immune reactions, while the host evolves towards masking or deleting the 
carbohydrate binding sites used by the invader. Therefore, some host-glycans may have lost their 
ancient physiological binding partners and functions over time.
12
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Table 1: Diversity of glycan functions 
functional
category 
Examples 
protective,
stabilizing,
organizational,
and barrier 
functions.
The glycocalyx represents the outer protective layer of the cell. 
Glycans attached to matrix molecules and proteoglycans mediate 
interactions that are important for the maintenance of tissue structure, 
porosity, and integrity. Densely O-glycosylated proteins such as 
mucins produce a physical barrier on surfaces. Solubility of excreted 
proteins may also be increased by addition of glycans. 
susceptibility to 
proteases
Glycans protect proteins from proteolytic degradation. To overcome 
O-DGalNac barriers (mucin type O-glycans) in Trichoplasia ni,
baculoviridae produce a protease that specifically degrades O-glycans 
(10).
protein folding in 
the ER 
The ER chaperones calnexin and calreticulin bind to incorrectly 
folded proteins in the ER through mono-glucosylated N-glycans and 
retain the glycoprotein in the ER, where it is refolded (reviewed in ref. 
7).
protein sorting in 
polarized cells 
O-glycans (O-DGalNac) have been shown to be a necessary factor for 
targeting specific proteins to apical membranes of polarized cells 
(reviewed in ref. 11).
trafficking and 
targeting to 
lysosomes  
Man-6-phosphate on N-glycans is a signal that targets proteins to 
lysosomes (reviewed in ref. 12).  
Exogenous enzyme can be targeted to lysosomes of macrophages 
from enzyme deficiency patients by terminal Man on N-glycans in 
patients with Gaucher’s disease (reviewed in ref. 13). 
recognition of 
glycans by 
antibodies  
Blood groups A, B and 0 differ in the structure of glycans displayed 
on their glycoconjugates. These glycans define the major transfusion 
incompatibilities between humans. 
1% of human IgG antibodies are directed against the GalD1,3Gal
epitope (14), which is found on glycoconjugates from most animal 
cells but old world monkeys and primates.These constitute a 
majorxenotransplantation barrier.
13
Introduction 
recognition of 
host glycans by 
invading
microbes 
N- and O-glycans, glycosphingolipids and proteoglycans can serve as 
(co-) receptors for many bacteria, viruses and other parasites as 
Bordetella pertussis, Giardia lamblia or Entamoeba histolytica to 
name a few (see as well http://sugarbinddb.mitre.org/)
modulation of 
binding affinities 
of receptor and 
ligand
O-Fuc initiated O-glycans modulate the affinity of the Notch receptor 
with its ligands Delta and Serrate in D. melanogaster (15). 
direct receptor 
response
modulation
Tyrosine auto-phosphorylation of the EGF receptor is regulated by the 
presence of gangliosides, a class of glycosphingolipids (reviewed in 
ref. 16) 
range or 
specificity of 
hormone 
function
Glycosylation variants of human thyroid-stimulating hormone have 
physiological properties that have been shown to selectively activate 
signal transduction through either the cAMP or inositol phospholipid 
hydrolysis pathways (17). 
range or 
specificity of 
growth factors 
Heparan sulfate proteoglycans shape gradients of growth 
factors/morphogens like the FGF-, TGFE- and the WNT family. 
intracellular
signalling
Several intracellular signalling and chromatin proteins carry O-
EGlcNAc, including RNA polymerase II transcription factors. 
Functions include nuclear transport, assembly into multimeric 
complexes, sensoring of cellular energy and regulation of 
phosphorylation (reviewed in ref. 18). 
Secretion rate 
and circulatory 
half life 
Desialylated N-glycans on erythropoietin (EPO) are trapped in the 
liver and excreted more quickly, tetra-antennary N-glycans are more 
active in vivo than bi-antennary N-glycans (19). Similarly, sulfate-
bearing O-Man initiated O-glycans increase the circulatory half-lifes 
of pituitary glycoprotein hormones (20). 
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5 Concepts of glycan synthesis 
DNA, RNA and proteins are the products of specific templates, thus a given template DNA 
sequence will code for a unique amino acid sequence. In contrast, glycans are produced in an 
“ordered melting pot”or on an “assembly line” (Figure 5). Moderately simplified, a model of 
glycan formation can be considered to comprise four steps: 
1. Synthesis of activated monosaccharides in the cytosol from precursor-substrates by a 
large biosynthetic machinery (see section 6.1). 
2. Transport of activated monosaccharides by specific transporters into the subcellular 
compartments where glycosylation reactions take place (see section 6.2). 
3. Catalysis of the first glycosylation reaction by initiating GTs. Thereby a mono- or an 
oligosaccharide is transferred onto proteins or lipids (see section 6.3.1).
4. Elongation of the glycan (see section 6.3.2). Thereby, elongating GTs utilize the product 
of the preceeding GT as acceptor-substrate.  
“Melting pot”
synthesis
lti  t
t i
Template driven
synthesis
l t  i
t i
GT1 GT2
GT3 GTn
Figure 5: Outline of glycan synthesis. Left: Template driven synthesis of proteins. DNA is the 
linear template for the corresponding RNA, which in turn is the template for the synthesis of a 
protein. Right: The glycan produced by a cell is determined by the presence of the corresponding 
GTs, transporters and the type of activated monosaccharides. The glycan may be elongated in 
different ways, depending on which GT is present in the cell and on the presence of the acceptor and 
donor-substrate.
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Unlike DNA, RNA and proteins, glycans can also be branched. A proofreading system for 
glycans does not seem to exist. Differences in the cellular set of GTs produce microheterogeneity 
of glycans within the same glycoconjugate as well as differences between tissues, developmental 
stages, neoplastic conditions and mutants for parts of the glycosylation machinery. The 
composition of glycans also depends on the exact localization of GTs along the secretory 
pathway. Taken together, the synthesis of glycans and the consistency of the glycan structures 
produced in a cell rely on the presence of the activated monosaccharide and on the presence of 
the GT at its correct location. 
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6 The glycosylation machinery 
6.1 Activated monosaccharides 
Carbohydrates are taken up as nutrients by transporters or synthesized within the cell. In 
eukaryotes, there are two types of transporters that translocate their substrates from outside the 
cell into the cytoplasm. One type includes energy-independent facilitated diffusion transporters, 
such as the family of GLUT proteins (glucose transporter) (21). A second type of carbohydrate 
transporters is energy-dependent. The family of sodium-glucose co-transporters (SGLT) (22) is 
found for example in epithelial cells of the intestine where absorption of nutritional 
carbohydrates takes place. Cellular glycans constitute another source of monosaccharides. 
Salvage pathways are fuelled by the disintegration of cellular glycans, which occurs at low pH in 
the lysosomes by glycan specific endo- and exoglycosidases, thereby liberating monosaccharides 
from glycoconjugates. Absence or inactivation of glycosidases may lead to a severe imbalance in 
the carbohydrate metabolism and lead to storage disorders (reviewed in ref. 23). 
Table 2: activated monosaccharides 
monosaccharide activated form 
Glc UDP-Glc, DolP-Glc 
Gal UDP-Gal 
GlcNAc UDP-GlcNAc 
GalNAc UDP-GalNAc 
GlcA UDP-GlcA 
IdoA UDP-GlcA1
Xyl UDP-Xyl 
Man GDP-Man, DolP-Man 
Fuc GDP-Fuc 
Sia CMP-Sia 
1IdoA is epimerized from GlcA after transfer to the glycan chain (c.f. section 8). 
Activated monosaccharides are produced in the cytoplasm, with the exception of CMP-Sia, 
which is synthesized in the nucleus and exported to the cytoplasm. Once the sugars are available 
as monosaccharides, they are activated by the addition of high-energy groups, these are mono-
/diphosphonucleotides (UDP, CMP and GDP ) and dolichylphosphate. Dolichylphosphomannose 
(DolP-Man) and dolichylphosphoglucose (DolP-Glc) are synthesized from the nucleotide 
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activated sugars GDP-Man and UDP-Glc and are used in the ER for the synthesis of O-
mannosylated, C-mannosylated and N-glycosylated glycoconjugates, as well as for steps in the 
GPI-anchor synthesis. The activated monosaccharides used for glycan synthesis by animals are 
summarized in Table 2. The synthesis of activated monosaccharides is regulated by feedback-
inhibition or activation of enzymes. These regulatory steps prevent the organism from 
consequences of an imbalanced uptake of monosaccharides (Figure 6). 
Gal Glc
Gal-D-1-P
UDP-D-1-Gal UDP-D-1-Glc
Glycogen
galacto-
kinase
UDP-GlcA
UDP-Xyl
galactose-
isomerase
G
al-1-P
uridylyl-
transferase
G
luco-
kinase
Glc-6-P
Glc-D-1-P
DolP-E-1-Glc
U
D
P-G
lc
6-D
H
U
D
P-G
lcA
decarboxyl-
ase
UTP-Glc-1-P
uridylyl-
transferase
glycogen
synthase
glycogen
phosphorylase
UDPglucose:
dolichyl-phosphate
E-D-glucosyltransferase
glucose
phospho-
m
utase
G
lucose-6-
phosphatase
Figure 6: Excerpt of the activated monosaccharide synthesis pathway. Glucose is the central 
metabolite for de novo synthesis of activated monosaccharides. All activated monosaccharides can be 
synthesized from glucose. Storage and synthesis of glycogen, the cellular storage form of glucose, is 
additionally regulated according to the energy requirements of the cell. Synthesis of an activated 
monosaccharide may be controlled by feed-back inhibition as exemplified by UDP-Xyl inhibiting 
UDP-Glc-6-dehydrogenase (red arrow). Figure modified from (24). 
6.2 Intracellular transport of activated monosaccharides 
Glycosylation reactions primarily take place in the lumen of the ER and the Golgi apparatus, 
while the synthesis of activated monosaccharides is located in the cytosol. Therefore, activated 
monosaccharides need to be translocated into these organelles. The transport of nucleotide 
activated monosaccharides is carried out by specialized proteins, nucleotide sugar transporters. 
Several of these transporters have been cloned and are located in the membranes of ER and/or 
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Golgi, depending on whether their transported substrate is required there (25, 26). Maintenance 
of the concentration of activated monosaccharides in the organelle is also achieved by 
transporters, since they have been found to act as antiporters, exchanging monophosphorylated 
nucleotides (products of glycosylation reactions and a subsequent nucleotide diphosphatase 
reaction) with nucleotide activated monosaccharides in equimolar ratio (27). For example, 
several transporters of UDP-nucleotide sugars have UMP as a common antiporter (28).  
6.3 Glycosyltransferases 
Once the activated monosaccharide has reached the site of glycan biosynthesis, they are utilized 
by glycosyltransferases (GTs) to glycosylate proteins or lipids. GTs generate a glycosidic bond 
between the anomeric carbon of an activated saccharide and an acceptor. GTs can be classified 
into initiating (glycosylating aglycones) and elongating (glycosylating glycoconjugates on their 
glycans) enzymes. 
Donor substrates for glycosylation-reactions are mono- or diphosphonucleotide-
Dmonosaccharides, DolP-E-monosaccharides or a DolPP-activated oligosaccharide (see section 
6.3.1 and 8.1). If the transferred monosaccharide retains the anomeric configuration of the donor 
monosaccharide (E for DolP – monosaccharides and D for nucleotide-monosaccharides), the 
transferase mechanism is defined as retaining, while GTs that change the anomericity of the 
transferred monosaccharide are inverting GTs (29). GT reactions are specific as they normally 
catalyze the formation of one linkage between a specific donor and a specific acceptor only 
(glycan, protein domain or ceramide), although there are some exceptions to this rule (30, 31). 
The “one enzyme - one linkage” concept (32) implies the presence of a large number of GT 
encoding genes, given the diversity of glycans. Indeed, it is estimated that over 200 GTs exist in 
the mammalian genomes (33) and that some 0.5 to 1% of the human genome code for 
constituents of the glycosylation machinery (34). 
As a first approximation, post-translationally acting GTs are suspected to be arranged in an 
assembly line in the Golgi, where early acting enzymes are more concentrated in the cis-Golgi,
intermediate acting enzymes in the medial-Golgi, and those adding terminal structures in the 
trans-Golgi. They may, however, also be found on the cell membrane or secreted into body 
fluids (35) for unknown reasons, where the concentration of activated monosaccharides is too 
low to carry out transferase reactions. The catalytic domain is sometimes separated from the N-
terminus of the enzyme by cleavage through proteases near the stem region (36, 37), which 
might be another step in the regulation of glycan production. 
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Failure to localize a GT correctly may result in the loss of the glycan chain (38). Indeed, a 
mutation in the COG7 gene encoding a Golgi vesicle protein has been shown to result in 
Congenital Disorder of Glycosylation -IIe (39). Other mechanisms besides those involving 
trafficking factors may also apply to localize GTs. A first model predicts that the length of its 
transmembrane domain determines the degree of trans-Golgi localization, since membrane 
thickness increases with a gradually higher cholesterol and glycolipid concentration from cis- to 
trans- Golgi (40). Another hypothesis is that inclusion of GTs into constitutively formed 
secretory vesicles is blocked upon di- or oligomerization of GTs and that GTs therefore remain 
in the Golgi (41). Indeed, Golgi localized GTs have been shown to form dimers and other 
complexes in vivo and in vitro (42-47). 
6.3.1 Initiating Glycosyltransferases
Initiating GTs add the first unit of a glycan chain to nascent or folded proteins in the ER or as 
post-translational modifications in the Golgi. Their acceptor substrates are proteins, ceramide or 
dolichophosphate and their donors may be nucleotide activated monosaccharides, lipid activated 
monosaccharides or the preassembled lipid-linked oligosaccharide Glc3Man9GlcNAc2 (Table 3). 
For protein glycosylation, the sequence context of the amino acid to be glycosylated is important 
as well as the 3D structure and the accessability of the site within the protein. Thus, not all amino 
acids within potential glycosylation motifs are glycosylated. On the other hand, some O-D-
GalNAc glycosylation initiating GTs require peptides, which are glycosylated at an adjacent site 
(48). Glycosphingolipids are formed by attachment of Glc or Gal to ceramide at the cytosolic 
face of the Golgi Apparatus (49, 50), implying, that the product is flipped into the lumen of the 
Golgi before elongation can occur. Multi-enzyme complexes which transfer preassembled 
glycans onto proteins are present in the N-glycosylation pathway and in the GPI anchor synthesis. 
In the N-linked pathway, the glycan is preassembled on a lipid carrier and the 
dolichylpyrophosphate-linked oligosaccharide GlcNAc2 Man9 Glc3 is transferred en bloc onto 
proteins by a multisubunit protein complex in the ER membrane to asparagine residues on 
nascent proteins. This complex is termed the oligosaccharyltransferase (c.f. section 8.1). 
Differently, preassembled GPI anchors from the cytoplasmic side of the ER (pEtn-Man3-GIcN-
acyl-P-lnositol) are flipped into the ER lumen und transferred by a large enzyme complex en
bloc onto proteins by a transamidase-reaction.
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1. MS-D-NDP + aglycone MS- aglycone + NDP
2. MS-E-DolP + aglycone MS- aglycone + DolP
3. Glc3Man9GlcNAc2-E-DolPP + aglycone Glc3Man9GlcNAc2- aglycone + DolPP
4. PI-Man3GlcN-D-pEtn + speptide-aglycone PI-Man3GlcN-D-pEtn – aglycone + speptide
Figure 7: Initiating reactions. Activated monosaccharides (MS) or preassembled activated 
oligosaccharides are transferred onto proteins or lipids by initiating GTs (reactions 1-3). GPI-anchor 
modification of proteins (reaction 4) is not a GT reaction since it involves transamidation and hence 
cleavage of a signal peptide (speptide). 
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Table 3: Glycan types and their initiating glycosyltransferase reactions in animals 
Glycan type acceptor, peptide sequence1 Donor substrate Localization of 
transfer 
Lipid linked 
oligosaccharide
DolP  UDP-GlcNAc 
(to give DolPP-
GlcNAc)
cytosolic face 
of ER 
N-glycans Asn-X-Ser/Thr (X  Pro) Glc3Man9GlcNAc2-
DolPP
ER-lumen 
O-glycan types: 
O-GalNAc
O-Glc
O-Fuc
EGFR
TSP
O-Man
Ser/Thr
2http://www.cbs.dtu.dk/services/
NetOGlyc/
Cys1XxxSerXxxProCys2 (51) 
Cys2XxxXxxGlyGlySer/ThrCys
(51)
TrpXxx5CysXxx2/3Ser/ThrCys
Xxx2Gly (52) 
?
UDP-GalNAc



UDP-Glc
GDP-Fuc

DolP-Man
cis-Golgi  
?
ER (53) 
ER (54) 
Proteoglycans variations of SerGly motifs (55) UDP-Xyl ER and/or cis-
Golgi (56) 
Glycosphingo-
lipids
Ceramide UDP-Glc, UDP-Gal cytosolic face 
of Golgi (49) 
C- Man TrpXxxXxxTrp DolP-Man ER? (57) 
O-GlcNAc 2Ser, Thr 
http://www.cbs.dtu.dk/services/
YinOYang/
UDP-GlcNAc nucleus, 
cytoplasma 
GPI anchors 2http://mendel.imp.univie.ac.at/ 
SEQUENCES/gpi-biosynthesis/
and (58) 
GPI lipid anchor3 cytosolic face 
of ER 
1sequences are still being refined, 2complex prediction and computational methods as neural network 
algorithms are preferred,3varies strongly between species, often: PI-Man3GlcN-pEtn.
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6.3.2 Elongating glycosyltransferases 
Elongating GTs in the Golgi catalyze the transfer of monosaccharides from mono- (Sia) or 
diphosphonucleotides (all other monosaccharides) onto glycans consisting of one or several 
monosaccharides. Elongating GTs at the ER membrane are primarily involved in the assembly of 
the N-glycan precursor lipid and the GPI-anchor.
The linkages produced classify elongating GTs. For example, E1,4 GTs form a linkage between 
theE anomeric carbon of the transferred monosaccharide and the C-4 attached hydroxyl group of 
the acceptor monosaccharide. There are D and E 1,2, 1,3, 1,4, 1,6 hexosyl- and pentosyl-
transferases (Table 4). The anomeric carbon of Sia is C-2 and linkages produced by SiaTs are 
described accordingly.
MS-D-NDP  +  glycan MS-D/Ex, y glycan +  NDP
Mn2+/Mg2+
D/Ex,y GT
Figure 8: Elongating GTs catalyze the transfer of a monosaccharide (MS) from an activated MS 
onto a glycan in a specific linkage. Transfer occurs, depending on the specificity of the GT, onto Dor
E anomeric terminal monosaccharides. Most GTs display absolute requirement of Mn2+ as co-factor, 
exceptionally, Mg2+ is the necessary co-factor. 
Sequence homologies between GTs that catalyze a specific linkage are higher than homologies 
between GTs using the same donor or acceptor substrates. This means that a E1,3 GalT is more 
homologous to a E1,3 GlcNAcT than a E1,4 GalT to a E1,3 GalT ((3) and section 9, Figure 21) 
indicating that the donor substrate is more easily changed than the linkage for most families. 
This rule does not apply to FucTs and SiaTs (Figure 10), whose sequence similarity is higher 
among each other than among enzymes transferring the same D-hexoses. 
Even if there are many homologous regions between members of a GT-family, sequence 
conservation at the DNA level is low, which has limited the use of DNA hybridisation 
techniques to the cloning of sialyltransferases (59). Therefore, computational sequence 
comparison at the protein sequence level (60) is used for the identification of cDNAs putatively 
encoding GTs that generate a specific linkage while donor and acceptor specificities of the 
transferase are less easily determined (47, 61).  
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Table 4: Elongating glycosyltransferases acting on glycans of animal proteins or 
glycosphingolipids
donor
substrate
linkages
catalyzed
1EC numbers 
UDP-GlcNAc E3
E4
E6
D4
E2





UDP-GalNAc E4
D3
E3
E1,6




UDP-Glc D4
D1,3

UGGT
UDP-Gal D3
D4
E4
E3




UDP-GlcA E3 
UDP-Xyl - n.d.
GDP-Man5 D1,2
D1,3
E4
D1,6




GDP-Fuc D1,3/1,4
D1,2
D1,3
D1,6




CMP-Sia D2,8
D2,3
D2,6



1enzyme EC numbers were compiled from: http://www.brenda.uni-koeln.de.
2not cloned, linkage based on data from purified enzyme analysis, no sequence data available. 
3GlcTs ALG 6, 8 (D1,3) and 10 (D1,2) use DOL-P-Glc as donors and have not yet been assigned EC 
numbers nor has UDP-Glc: glycoprotein GlcT (UGGT). 
4in contrary to plants and prokaryotes, no elongating activity with UDP-Xyl has been observed in 
animals yet. 
5ALG ManTs are located at the ER membrane and elongate the N-glycan DolPP- precursor 
oligosaccharide.
in bold: sequences of human (mostly) enzymes that were used in Figure 10 for an alignment. 
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Figure 9: Elongating Golgi GTs catalyzing different reactions. Phylip-tree (62) of a ClustalW- 
alignment (63). Sequences refer to Table 5. hs: homo sapiens, drome: Drosophila melanogaster, scfo: 
sus scrofa.
Alignments show that FucTs and SiaTs, although catalyzing different linkages, display similarities 
among each other, while at this stage, the only moderately significant sequence similarity between 
transferases catalyzing the same linkage is found between two D1,3 GTs. 
25
Introduction 
7 Drosophila melanogaster as a model system to study 
glycosylation
Glycosylation has recently attracted more attention because several diseases have been found to 
be related to glycosylation-defects in humans (64). For the N-glycosylation pathway in the ER, 
many human-orthologous genes encoding GTs were characterized in yeast mutants (reviewed in 
ref. 24). However, yeast Golgi glycans differ substantially from those found in multicellular 
organisms (65). Thus, to identify animal-relevant carbohydrate active enzymes, other procedures 
like selecting for resistances to cytotoxic plant lectins in mammalian cell lines have been used 
(66). These biochemical screens yielded a large number of mutant cell lines and led to the 
identification of transporters of activated-monosaccharides and GTs. In cell lines, phenotypes are 
more difficult to detect than in multicellular organisms, which often display lethal consequences 
of disturbed glycan-mediated intercellular interactions. Therefore, model organisms are 
indispensable to study the functions of specific glycans.
In contrast to other carbohydrate active enzymes, GTs remain the glycobiologist’s central target 
for knock-out models, if elimination of a specific glycan and observation of the systemic effect is 
desired, because most GTs are specific for both glycan-type and catalyzed linkage. Indeed, 
reverse genetics approaches with GT-knock-out models in mice have proven powerful tools for 
the investigation of both physiological and developmental issues in mammals (reviewed in 67).  
The opposite approach is to look for candidate genes coding for carbohydrate active enzymes by 
screening the genome of multicellular organisms and phenotyping the mutants - an approach too 
cumbersome and expensive with mice but proving suitable to find carbohydrate active enzymes 
in C. elegans, for example. A screen for mutations in the vulval development of C. elegans
revealed genes encoding GTs and transporters that are components of the proteoglycan synthetic 
pathway (68, 69). Another model system that can be used for screens is D. melanogaster, which 
has the largest number of established mutants of all model organisms. Even more, genetic 
interactors of GTs may be found by crossing mutants with phenotypically similar ones, or 
mutants that are otherwise (typically by bioinformatics) presumed to be interactors (70, 71). 
Analysis of double mutants may reveal phenotypically scoreable interactions in the system under 
examination. 
A genetic interactor could be any glycosylated protein or any that needs to interact with a 
glycoprotein or glycolipid to carry out its functions. Examples would be specific glycoconjugates, 
lectins or other carbohydrate active proteins like transporters. Secondary interactors could be 
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transcription factors, whose signal is integrated in parallel or downstream of a glycoconjugate- 
mediated function (e.g. 72). Further analysis and epistasis experiments can be employed to 
determine the level at which the signal is integrated. For example, double mutants for a 
promiscuous transporter encoded by the gene fringe connection with two GTs involved in either 
proteoglycan or O-glycan synthesis displayed a stronger phenotype than the individual mutants 
(73), also genetically indicating the cooperation of these carbohydrate active proteins. 
Taken together, the wealth of publically available mutants, genetic amenability and a century of 
experience with this model organism render D. melanogaster the organism of choice to search 
for interactors of glycans. 
bioinformatics candidateglycosyltransferase
cloning and expression,
in situ hybridisation activity, linkage
knock-out/down, protein
analyis, GSL analysis, lectin
binding
in vivo substrate, 
function, glycan
identification,
test for functional
redundancy of GTphenotyping, clonal analysis, 
cross with candidate
interactors, screen in mutant
backgrounds, mapping, 
epistasis experiments, 
overexpression
identification of
interacting genes
glycan array,
co-precipitation,
RNA array,
purification of interactors
nature of interaction
(primary, secondary)
Figure 10: Steps in the analysis of glycan functions. A broad area of techniques encompassing 
genetic analysis as well as biochemical methods and glycan structure determination is required to 
find and describe interactors of glycans. 
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8 Drosophila melanogaster glycans
The first glycosylation mutant described as such in D. melanogaster was found in a screen 
scoring the binding of a CNS specific antibody directed against a glycan epitope. Absence of 
binding in the mutant CNS indicated a difference in the glycan structure of the mutant. The locus 
was dubbed neuronally altered glycosylation (74). While that gene lacks molecular 
characterization to date, several glycosylation pathways and glycoconjugate classes have been 
described in D. melanogaster (Table 5). D. melanogaster has been shown to carry out N-linked 
glycosylation, GPI anchor synthesis, O-Fuc initiated O-glycosylation, O-mannosylation, mucin-
type O-glycosylation, glycosaminoglycan- and glycosphingolipid- synthesis (reviewed in refs. 75 
and 76). Glycans may be produced only during specific developmental phases (77), be restricted 
to a rare tissue or occur in low abundance for other reasons. Thus, methods involving 
glycoconjugate-purification from whole animals, glycan release and subsequent glycan structure 
determination cannot be expected to be comprehensive. Cloning and characterization of GT 
enzymes can give important clues for the identification of novel glycan structures. In the 
following sections, biosynthesis and functions of some already characterized glycan classes are 
discussed.
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Table 5: Glycoconjugate classes described in Drosophila melanogaster
glycoconjugate class presence in  
D. melanogaster?
monosaccharides in  
D. melanogaster glycans1
N-glycans yes (78, 79) GlcNAc, Man, Fuc, Glc 
O-glycan-types: 
O-GalNAc
O-Glc
O-Fuc
O-Man
yes (48), [III] 
unknown
yes (80) 
yes2 (81) 
GalNAc, Gal 
unknown
Fuc, GlcNAc 
Man
Glycosphingolipids yes (82) Glc, Man, GlcNAc, GalNAc, Gal, GlcA 
C-glycans unknown3(83)  
GPI-anchors yes (84) no structural studies to date 
Glycosaminoglycans yes (85) GalNAc, GlcNAc, GlcA, IdoA, GlcN, 
sulfated monosaccharides 
Cytoplasmic/nuclear 
glycans
yes (86) GlcNAc 
1sialic acids may be also be present on Drosophila glycans (discussed in ref. 76) 
2presence of O-Man glycans is inferred from mutants in a O-ManT-homologous enzyme, not from 
structural studies. 
3D. melanogaster cell lines do not carry out C-mannosylation. 
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8.1 N-Glycans 
Biosynthesis of N-Glycans (Figure 11) starts at the cytoplasmic side of the ER membrane, where 
stepwise addition of GlcNAc and Mannose by GTs using diphosphonucleotide monosaccharides 
leads to the assembly of Man5GlcNAc2 on the high-energy lipid carrier dolichylpyrophosphate 
(DolPP). The associated GTs have not been cloned from D. melanogaster. Their orthologues are 
called ALG (for asparagine linked glycosylation). Upon action of a flippase (87), this structure is 
translocated into the lumen of the ER, where it is further elongated by GTs using DolP activated 
monosaccharides. Oligosaccharyltransferase (OST) transfers Glc3Man9GlcNAc2 from their 
activator DolPP onto asparagines (Table 3) Glucosidases I and II trim the Glc residues on N-
glycans. Then, secreted and membrane glycoproteins have to pass the ER protein quality control 
to enter the Golgi (reviewed in ref. 7). If the protein is not folded properly, UDP-
Glc:glycoprotein GlcT (UGGT) functions as a folding sensor and reglucosylates the N-glycan, 
recognizing the innermost GlcNAc within exposed hydrophobic regions. Upon recognition of the 
terminal glucose by the lectin chaperones calnexin and calreticulin, the protein undergoes 
another folding cycle. If, after release, the N-glycosylated protein is folded correctly, the 
terminal Glc is cleaved off and the protein exits the ER for the Golgi. A protein, which is not 
folded correctly for an undetermined number of cycles is targeted for proteosomal degradation in 
the cytosol in a process called ER associated degradation (88). Once arrived in the Golgi, the 
processing of N-glycans in Drosophila has been shown to include trimming up to complete 
deglycosylation of N-glycan sites (89) and a number of reglycosylation reactions. Recent studies 
(79) demonstrated the presence of difucosylated N-glycans and suggested that N-glycans in D.
melanogaster equal vertebrate N-glycans in terms of diversity, although no sialylated structures 
have been published to date. 
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Figure 11: N-glycosylation biosynthetic pathway. N-glycosylation at the ER membrane (left) is 
conserved in most eukaryotes and involves the action of GTs (ALG, asparagine linked glycosylation) 
using diphosphonucleotide activated Man and GlcNAc on the cytoplasmatic side of the ER or DolP-
activated Man and Glc on the luminal side of the ER to produce a DolPP-assembled glycan. 
Glc3Man9GlcNAc2 is then transferred en bloc onto proteins and serves for protein quality control by 
the lectin-chaperones calnexin and calreticulin. UDP-Glc:glycoprotein GlcT acts as a sensor for 
incompletely folded proteins. Golgi associated processing (right) is achieved by mannosidases, 
which trim the high-mannose N-glycan. All structures between Man9GlcNAc2 to Man2 GlcNAc2 are 
present in D. melanogaster. GlcNAcT-I and –II are responsible for N-glycan structures with terminal 
GlcNAc, and at least 2 FucTs for the generation of D3 and D6 core-fucosylated N-glycans. 
No systematic analysis on mutations in the N-glycosylation pathway in D. melanogaster has 
been performed to date. Studies on the requirement for N-glycosylation are limited to an 
embryonic lethal mutation in an ALG3 homologous gene (an D1,3 ManT) encoded by l(2)not
(90). In humans, a missense mutation in this gene is characterized by microcephaly, severe 
epilepsy and minimal psychomotor development (91). 
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8.2 Proteoglycans 
Proteoglycans are proteins carrying glycosaminoglycans (GAGs). The GAGs described in D.
melanogaster, heparan sulfate (HS) and chondroitin sulfate (CS), are linear and unbranched 
polymers of disaccharides synthesized from an amino sugar and an acidic sugar (Figure 12). 
They contain regions which are sulfated to various extents. The physico-chemical properties 
shared with all non-fibrillous polymers of carbohydrates are the capability to bind large amounts 
of water and to form gels. The negative charge results from the content of acidic sugars and 
sulfate groups and also allows cation binding. The size of these polysaccharides reaches 100 kD 
for HS. C. elegans vulval development is severely disturbed in mutants for GAG synthetic genes 
because the vulval extracellular space fails to expand, an effect directly related to reduced water 
uptake of the tissue failing to produce GAGs.
CS consists essentially of repeated units of the disaccharide [GalNAcE1,4GlcAE1,3]n while HS 
is a strongly modified chain with the backbone disaccharide [GlcNAcD1,4GlcAE1,3]n. GAGs 
commonly found in vertebrates like dermatan sulfate [GlcA/IdoAE1,3GalNAcE1,4]n and keratan 
sulfate [GalE1,4GlcNAcE1,3]n have not been described in D. melanogaster to date and 
hyaluronan [GlcAE1,3GlcNAcE1,4]n is absent (92). The main GAG produced during D.
melanogaster adult life and embryonic development is HS. This GAG is also maternally 
deposited into the embryo (93). CS, on the other hand, is produced primarily during larval stages 
(93). CS has a lower content of IdoA than HS and the only described sulfation is carried out by a 
not yet cloned CS 4-O-sulfotransferase (94).While mutations affecting CS synthesis impact 
embryogenesis in C. elegans (95), no D. melanogaster mutant specifically affected in CS 
formation has been described to date. 
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Figure 12: GAG biosynthesis. Enzymes implicated in GAG synthesis or modification are boxed. 
Question marks after enzyme-names indicate high sequence similarity of the isoform to known 
human or C. elegans enzymes carrying out the same reaction but lacking complete characterization. 
References for the listed genes are given in the appendix. 
Both polymers are assembled in the Golgi from the common linker sequence GlcAE1,3 GalE1,3
GalE1,4 XylE1,1 -O-Ser within Ser/Gly- rich regions (96). After the steps leading to the primer 
tetrasaccharide, an initiating GlcNAcT encoded by brother of tout-velu (97) commits the growing 
chain to the HS fate by a transfer of GlcNAc to GlcA or adds GalNAc to GlcA to synthesize CS. HS 
synthesis continues by addition of GlcA and GlcNAc. Both activities are catalyzed by a co-
polymerase consisting of two enzymes encoded by sister of tout-velu and tout velu (98). After the 
synthesis of the backbone structure, the polymer is strongly modified by sulfation and isomerization. 
These modifications include GlcA epimerization to IdoA, GlcNAc N-deacetylation to glucosamine 
(GlcN) and N-/O-sulfation. Mutants in HS sulfation have been shown to produce strong and/or lethal 
phenotypes (99-101), substantiating the importance of sulfation within HS chains.  
High size, charge and water uptake reduced the perception of GAGs for a long time to a kind of 
“fly-paper” to which about any ligand would bind with low specificity. However, mutants in 
GAG biosynthesis paint a subtler picture about the influence of GAGs on the development of D.
melanogaster, at least as far as HS is concerned. As shown in vertebrates, GAGs may be very 
specific in their affinity to proteins. In fact, proteins were shown to bind to molecularly defined 
contiguous sequons in HS (102) and to discontinuous domains forming a loop (103).  
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Figure 13: Growth factors and morphogens bind HS as shown in vertebrates and in D.
melanogaster. Interferon gamma (IFNJ) binds to HS loops and fibroblast growth factors (FGFs) bind 
different sequons with graded strength. FGF-HS/FGF-1 interaction may fulfil various purposes. For 
example, modulation of the binding of FGF to HS may regulate FGF-FGF receptor complex 
formation, receptor dimerization and activation. Growth factor/morphogen-HS interaction may also, 
in addition to diffusion-control, serve to protect against proteolysis (104). Wingless (WG) also binds 
to HS and the Wingless gradient is shaped by the glypicans encoded by dally and dally-like protein. 
The sequon to which WG binds is unknown, though. 
The family of HS carrying proteins, known as heparan sulfate proteoglycans (HSPGs), 
encompasses glypicans, perlecans and syndecans. Glypicans are HSPGs that are anchored in the 
plasma membrane by a GPI-anchor. Perlecans and syndecans are HSPGs whose transmembrane 
domains ensure plasma membrane localization. It seems evident that the glycan moiety is 
indispensable for HSPG function, since different glypicans, perlecans and syndecans have been 
shown to similarly influence responses to secreted morphogens like FGF, Decapentraplegic, 
Wingless and Hedgehog (105-110), although their core proteins differ. 
Morphogens are secreted signalling molecules that form gradients in the embryo and in tissues. 
In short, morphogens are released by a distinct group of cells and are spread into the surrounding 
area. There, the concentration is differentially interpreted by the receiving cells and induces the 
expression of a position-specific set of genes (reviewed in ref. 111). For instance, the morphogen 
Wingless acts at a short range in the embryonic epidermis, regulating the activity of target genes, 
while as a long-range morphogen in the wing imaginal disc, it forms a stable gradient with a 
source localized at the boundary between ventral and dorsal compartments (reviewed in ref. 112). 
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Binding to HS is believed to influence diffusion and stability of the morphogens, helping to 
establish and maintain the gradient. 
The interaction of the morphogen Wingless with the HS biosynthetic machinery has been studied 
extensively. Direct interaction of HS with Wingless has been demonstrated in cell culture assays 
(105, 113), and mutant flies in HS chain polymerization display a disturbed Wingless gradient 
(114). Moreover, they display wingless loss-of-function phenotypes (98, 115) as do mutants in 
activated monosaccharide synthesis (116), in transporters of activated monosaccharides (73, 117) 
and in HS chain modifying enzymes (99-101, 107). 
Since individual morphogens also interact among each other genetically, it can be difficult to 
assess the relative importance of individual glycan-morphogen interactions. For example, 
Hedgehog and Wingless functions are interconnected by a feedback-loop during segment 
polarity determination, a process during which Hedgehog maintains Wingless transcription (118, 
119). Morphogen-response modulation by GAGs does not seem to be limited to D. melanogaster,
since mouse knock-out models in the tout-velu-orthologous gene Ext1 display embryonic 
lethality (120), while mutations in an EXT gene in humans is associated with multiple hereditary 
exostoses, benign bony tumours at the growth plate (121).
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8.3 Glycosphingolipids 
Glycosphingolipids (GSLs) are glycoconjugates that consist of one to several monosaccharides 
bound to ceramide (Cer). D. melanogaster synthesizes 3 types of GSLs: neutral, neutral 
zwitterionic and acidic zwitterionic (Figure 14). Zwitterionic GSLs have phosphoethanolamine 
(pEtn) covalently attached to GlcNAc residues and acidic zwitterionic GSLs are terminated with 
GlcA in addition to pEtn modifications. 
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Figure 14: Biosynthesis of D. melanogaster GSLs. pEtn: phosphoethanolamine, MacCer: 
ManE1,4Glc-ceramide. N: neutral, A: acidic (ending with GlcA) z: zwitterionic (carrying pEtn). 
Enzymes producing the indicated structures are boxed. The question mark denotes sequences with 
high similarities to characterized enzymes, and/or activities consistent with a possible role in the 
synthesis of the GSL species that lack pathway assignment. References for individual genes are 
given in the appendix.
GlcCer is produced by GlcT-1 at the cytosolic face of the ER and is thought to be subsequently 
flipped into the luminal face of the Golgi by action of an unknown flippase (reviewed in 122) or by 
an equivalent mechanism. Elongation by the E1,4 mannosyltransferase Egghead (123) yields 
ManE1,4GlcE1,1Cer. The next larger GSL species, N3, is produced through elongation by Brainiac 
([I],124). The first zwitterionic GSL is produced from N3 by a pEtn transferase, for which no 
candidate has been cloned to date, while candidates for the synthesis of the equivalent terminal 
linkages in Nz4- and Nz28, CG8536 and CG14517, have been recently cloned and GalNAcT activity 
was demonstrated on GlcNAcEwith both enzymes (125). D. melanogaster Nz5 synthase was cloned 
and biochemically characterized (126). The action of a E1,3 GalT on Nz5 yields Nz6. Nz6 synthase 
activity on GSLs catalyzes the same reaction as enzymes that generate the mucin type O-glycan 
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GalE1,3GalNAcD core1 [III]. Addition of GlcA to Nz6 produces the acidic GSL Az6. Enzymes for 
the generation of the acidic GSLs Az6 and Az29 may already be known, since three possible enzymes 
display GlcAT activity with GalE terminating acceptors (127). The enzyme catalyzing the elongation 
of Nz6 to Nz7 with GlcNAc is achieved by a yet unpublished E1,3 GlcNAcT as is the elongation of 
Nz28 to Nz29.  
Most of the GSL structures that are present in D. melanogaster (82) were identified in GSLs 
from different dipterans (128, 129), while already lepidopteran insects may have different and/or 
additional trisaccharylceramide core structures (124). GSLs are ubiquitous components of the 
animal plasma membrane and more than 400 species of GSLs have been reported, underlining 
the diversity of this class of glycoconjugates. While invertebrates seem to rely solely on GlcCer 
as a monosaccharyl-ceramide core (Figure 15), vertebrates also have GalCer. GSLs in 
vertebrates may be modified with sulfate-groups while nematode GSLs carry 
phosphatidylcholine groups instead of pEtn. Despite the enormous diversity of mammalian GSLs, 
mammals seem not to produce ManE1,4GlcCer (130, [I], [II]). Interestingly, the difference 
between the core structures ManE1,4GlcCer and GalE1,4GlcCer seems to be evolutionary rather 
than purely functional since substitution of ManE with GalE through transgenic expression of a 
mammalian E1,4GalT complements a lethal mutation in D. melanogaster egghead and 
GalE1,4GlcCer is elongated (130).
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Figure 15: Evolutionary diversity of GSL core-structures. Arthro- and mollu-series 
glycosphingolipids (GSLs) and four types of common mammalian GSLs are shown. 
A similarity between vertebrate and arthro-series GSL synthesis is the nature of the terminating 
monosaccharides. As with GlcA in D. melanogaster, mammalian GSLs are often terminally 
modified by acidic monosaccharides. For instance, Sia in mammalian GSLs is crucial for 
interactions with lectins like the myelin associated ganglioside receptor (131). In D.
melanogaster no endogenous lectin binding to GlcA has been reported yet.
While the GSL biosynthetic pathway has been studied extensively in the mouse by reverse 
genetics, corresponding GTs in invertebrates have not been thoroughly studied, except for the 
two loci brainiac and egghead in D. melanogaster, which have been genetically characterized 
without knowledge of their biochemical properties (132-136). 
During early embryonic development, brainiac and egghead mutants display gaps or multiple 
layers of follicle cells surrounding the oocyte/nurse cell complex (Figure 17). Additionally, 
brainiac alleles also display an overlarge CNS, inspiring the name of the gene (71). Germline 
clones, eliminating maternal transcripts from brainiac (137) and egghead (136) revealed that 
both genes are required in the germline. Both brainiac and egghead mutants display equivalent 
and non-additive phenotypes (71) and mutants showed equivalent and strong interactions with 
mutant alleles of the Transforming Growth Factor D (TGFD)/Epidermal Growth Factor Receptor 
(EGFR) pathway (137, 138). Therefore, egghead and brainiac wild-type action was placed into a 
parallel and cooperative pathway to the EGFR pathway during nurse cell/oocyte – follicle cell 
interaction (71).
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The biochemical data on the interaction between brainiac and egghead (130) confirmed those 
obtained by the genetic approach, both gene products acting in the same GSL synthetic pathway. 
On the other hand, the nature and the level of interaction(s) between GSL synthetic genes with 
components of the EGFR pathway remain unresolved to date. 
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Figure 16: The layer of follicle cells surrounding oocyte/nurse cell is affected by mutations at 
the GSL synthetic loci brainiac and egghead. A. representation of a wild-type nurse cell/oocyte – 
follicle cell monolayer complex. B. brainiac and egghead display gaps and multiple layers of follicle 
cells around the complex.  
Both transcripts are necessary in the germline (oocyte/nurse cells) and brainiac mutant embryos later 
display a fused dorsal appendage, which indicates defects in the specification of the dorsoventral axis 
of the chorion. Dorsoventral polarity defects can also be observed in alleles of the EGFR (necessary 
in the follicle cells) and its signal, encoded by the TGFD homologous gene gurken (required in the 
germline) (139, 140). However, EGFR and gurken alleles also display polarity defects in the embryo 
proper. Double mutants of brainiac or egghead with both EGFR and gurken alleles show stronger 
phenotypes than null alleles of EGFR or gurken mutants. 
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8.4 O-Fucose initiated O-glycosylation
Proteins, that are O-fucosylated typically contain EGFR repeats with the consensus sequence 
CX2G2S/TC (X is any amino acid and S/T the O-Fuc site) between the second and third 
conserved cysteine (141) or they contain thrombospondin 1 (TSR) repeats with the sequence 
WX5CX2/3S/TCX2G (52). Both TSR repeats and EGFR repeats are common modules on animal 
cell surface proteins.
EGFR repeats are 30-40 amino acids long and contain 6 cysteins that form 3 disulfide bridges, 
maintaining the structure of the module. EGFR repeats are found on receptors like EGFR, Delta, 
Serrate (Serrate orthologues are called “Jagged” in vertebrates) and Notch. While mammals 
encode two O-FucTs, only one gene encoding an O-FucT enzyme, neurotic, has been described 
in D. melanogaster to date (80, 142, 143). A E1,3 GlcNAcT encoded by fringe subsequently 
catalyzes the formation of the disaccharide GlcNAcE1,3FucD (15) on a subset of O-fucosylated 
EGFR repeats (Figure 17). In mammals, the disaccharide is sometimes elongated by E1,4 GalT-I 
and an D2,3 SiaT (51). However, there is no evidence yet that EGFR modules of D.
melanogaster are elongated any further than with GlcNAc. 
Fuc
GlcNAc
E3
D
Fringe
Neurotic
Figure 17: EGFR type O-Fucose glycosylation. Neurotic and Fringe catalyze the formation of the 
disaccharide GlcNAcE1,3FucD-Ser/Thr on EGFR modules in D. melanogaster.
The Notch protein contains 36 EGFR repeats and mediates a plethora of cell fate decisions 
during D. melanogaster development. For example, both positive and negative signals from the 
Notch signalling pathway regulate the differentiation of the central and peripheral nervous 
systems, the eyes, antennae and legs. Oogenesis and wing margin formation (Figure 18) are also 
systems that are influenced by Notch (144). Flies exhibiting notching at their wing edges 
inspired the name of Notch mutants. The ligands for the Notch receptor, Delta and Serrate 
interact with EGFR repeats on Notch, and O-Fuc initiated glycans on EGFR repeats modifies the 
affinity of the interactions between Notch and its ligands. The modulation of this receptor-ligand 
interaction made Fringe the best studied GT in terms of genetic analysis and many reviews have 
addressed Fringe in connection with its substrate, the Notch receptor (145-150). 
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Figure 18: Fringe modifies Notch-Delta/Notch-Serrate interaction in the wing disc. A thin stripe 
of activated Notch (i.e. Wingless producing) cells in the middle of the wing disc demarcates the 
border between its dorsal and its ventral portion (151), the border being the place where the wing 
blade is situated in adults. Although the Notch gene is initially expressed throughout the wing disc, it 
is only activated at its dorsal-ventral boundary upon interaction with two groups of cells, one group 
carrying Serrate and the other Delta on their surface (147, 152). Fringe is expressed in the dorsal 
compartment of the wing disc only, where apterous drives its expression (153, 154) and the Fringe 
product inhibits Serrate-Notch interactions in the dorsal compartment. Delta and Serrate levels are 
regulated across the dorsal- ventral border of the wing disc in a positive feedback loop and the Fringe 
product on Notch potentates Notch-Delta binding on the dorsal-ventral border (155). The E1,3
GlcNAcT Fringe is therefore necessary for wing blade formation. 
Clonal analysis in wing discs revealed internal ectopic wing margins at the border of adjacent 
fringe+ and fringe- clones (70), pointing towards a role of fringe in Notch mediated wing border 
formation. Genetic analysis showed that fringe acts cell-autonomously and in signal receiving 
cells (155). This result is consistent with biochemical data (15) indicating that only the Notch 
receptor and not its ligands Delta and Serrate, which also carry EGFR modules, are the substrate 
for the E1,3 GlcNAcT Fringe. The consequence of the modification of Notch-EGFR repeats by 
Fringe is that the Notch receptor binds much more to Delta and less to Serrate than without 
GlcNAc modification when assayed in vitro (15). 
The fringe phenotypes observed are not as strong as phenotypes of its biochemical precursor 
neurotic, which also impacts cell fate decisions in the developing CNS (156). This might 
indicate that fringe is only involved in processes during which the Notch receptor requires to 
distinguish between Delta and Serrate (reviewed in ref. 157). Whether this is the case in all 
developmental processes affected by fringe remains to be assessed. 
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8.5 Mucin Type O-Glycosylation 
Mucins are proteins that carry GalNAcD-O-Ser/Thr initiated glycans. Typically, mucin-type 
glycans are found on protein domains rich in Thr, Ser and Pro. Their synthesis is initiated by 
polypeptide DN-acetylgalactosaminyltransferases (ppGalNAcTs) in the cis-Golgi (158). This 
first step results in the generation of the Tn-antigen (159), representing GalNAcD-O-Ser/Thr.
Nine active D. melanogaster ppGalNAcTs have been cloned and characterized with respect to 
their activities to date (160-162).
mucin domain
(rich in Thr, Ser, Pro)
E3 core1,
T antigenTnppGalNAcT
core1 E3GalT
GalNAc
GalD
Figure 19. Mucin-type O-glycosylation in D. melanogaster has not yet been shown to extend the 
core1-structure, i.e. GalE1,3GalNAcD Ser/Thr. ppGalNAcTs act on mucin domains within proteins 
or are glycopeptide specific (mucins with GalNAc-O-Ser/Thr at an adjacent site) to produce the Tn 
antigen. Tn is extended to the T-antigen or core1 by core1 E3 GalTs.  
The family of ppGalNAcT enzymes can be categorized into activities that glycosylate peptides 
and activities that act on glycopeptides, carrying a Tn-antigen at an adjacent site. A 
subclassification of activities is achieved by their sequence-specificity. One reason for the high 
number of ppGalNAcT encoding genes may be the structural diversity of their substrates.
While highly complex mucin type O-glycans have been reported for C. elegans (163), D.
melanogaster mucin type O-glycans have not been established beyond the core1 structure 
GalE1,3GalNAcD -O-Thr/Ser. However, the limited number of structural studies (164, 165) 
precludes any conclusion regarding core1 elongation in D. melanogaster. Four core1 E1,3 GalT 
enzymes catalyzing the elongation of GalNAcDwith Gal have been cloned and characterized 
[III]. In mammals, only one core1 E1,3 GalT has been cloned to date (166). Mammals, however, 
present a previously unexpected factor in the regulation of mucin-type glycosylation. A core1
E1,3 GalT- specific chaperone, cosmc (core1 specific molecular chaperone) (167) prevents the 
GT from proteasomal degradation. Interestingly, the primary sequence of cosmc shares many 
features of the core1 E1,3 GalT itself (168). 
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Mucins provide a protective barrier and lubrication at the apical surface of epithelial cells (169) 
and are under discussion to provide targeting information as for example to the apical brush 
border membrane (170). In D. melanogaster, six mucin-type salivary gland secretion proteins 
(glue proteins) are found in large quantities in the salivary glands of third instar larvae (171), and 
salivary gland mucins were shown to be important for the entrapment and elimination of bacteria 
(172). Occurrence of the core1 structure in D. melanogaster has also been reported on 
haemocytes (173), on intercellular bridges between germline and somatic cells (174) and on 
several peptides involved in innate immunity (reviewed in refs. 175 and 176). Moreover, mucin 
type O-glycans on the anti-microbial peptide Drosocin have been demonstrated to increase its 
potency (164). In the latter case, however, a NMR study of glycosylated versus unglycosylated 
Drosocin has shown that the glycan itself is not implicated in the binding to microorganisms 
(177).
The scarcity of data on mutants in mucin type O-glycosylation disallows to draw conclusions on 
the importance or function of these glycans in D. melanogaster to date. However, one D.
melanogaster ppGalNAcT, encoded by Pgant35A (161, 178), was demonstrated to be essential 
and a deletion encompassing the Pgant35A locus leads to death during pupation (179). In 
humans, a mutation in a ppGalNAcT leads to tumoral calcinosis, a metabolic disorder 
characterized by massive calcium deposits in the skin and subcutaneous tissues (180). However, 
since both acceptor specificity and expression patterns of some ppGalNAcTs overlap, rescue 
with other ppGalNAcTs likely accounts for the lack of a visible phenotype for several 
ppGalNAcT knock-out models in mice (181, 182).
While no D. melanogaster mutant has been described for the formation of core1, a mouse knock-
out for the single core1 E3GalT demonstrated the importance of that activity in mammals since 
early embryonic lethality was observed (183). The core1 E3GalT1-null mice exhibited defects in 
angiogenesis and haemorrhages possibly caused by defective interactions between endothelial 
cells and the extracellular matrix. 
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9 E1,3 Glycosyltransferases of D. melanogaster 
As outlined earlier (section 7), the in vitro characterization of GTs is the first step toward 
understanding the functions of glycan chains.
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Figure 20: Structure of and reaction catalyzed by E1,3 GTs. Left: human GlcAT-I dimer (46, 
PDB:1KWS) in complex with UDP-GlcA (green) and Mn2+ (red). DXD motif (c.f. Table 6) in 
yellow. One monomer is drawn in ribbons, the other in backbone representation. Middle:. E1,3
GTs are type II trans- membrane proteins with a single transmembrane domain anchoring the protein, 
a short N-terminal domain and a longer C-terminal domain. The short N-terminus is located within 
the cytosol while the C-terminus, which includes the catalytic domain, lies in the lumen of the Golgi 
compartment.E1,3 linkages in D. melanogaster glycans are found in GAGs (section 8.2), GSLs 
(section 8.3), O-Fuc initiated O-Glycans (section 8.4) and mucin-type O-glycans (section 8.5).  
Right: Reaction catalyzed by E1,3 GTs. E1,3 GTs often require a pH between 5 and 7 and the 
divalent cation Mn2+ for activity (184). The catalytically active part of the transferase defines the 
donor and acceptor specificity of the transferase. With most E1,3GTs, the acceptor monosaccharide 
and its anomericity provides sufficient specificity for activity measurements, although a penultimate 
monosaccharide corresponding to the physiological substrate often increases the measured activity.  
Sequence alignments of characterized D. melanogaster GTs reveal clustering according to the 
linkage catalyzed and to some degree also by donor specificity (Figure 21). Along this line, the 
two D. melanogaster genes, brainiac (185) and fringe (70) were predicted to encode E1,3 GTs 
(186) by virtue of their sequence similarities to known bacterial enzymes. Similarly, owing to 
their cross-species homologies, as many as 21 candidate E1,3 GTs (Figure 22) can be retrieved 
using BLAST (60) searches.
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Figure 21: Unrooted ClustalW (63) tree of characterized D. melanogaster GTs with different 
donor and acceptor specificities. Sequence similarity among GTs is more related to the linkage 
catalyzed than to the donor specifity of the enzyme. For references see appendix. 
Enzymes: 1: CG14517, 2: CG8536, 3: CG9520, 4: CG8708, 5:CG13904-1, 6: CG2975, 7: CG3881, 
8: CG6207, 9: CG32775, 10: CG11780, 11: BOTV, 12: TTV (E4GlcNAcT, E3GlcAT, co-
polymerase), 13: BRN, 14: FRG, 15: EGH, 16: SOTV (E4GlcNAcT, E3GlcAT, co-polymerase).  
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Among the most conserved areas are four short motifs (Table 6). Mutations in motif I (TW), 
motif II (DXD) and motif IV (EDV) reduced or abrogated activity of a murine E1,3 GT (187). 
One would expect conserved E1,3 GTs to retain their donor and acceptor specificity, however, 
global sequence comparisons reveal that the degree of cross-species sequence similarity of 
orthologousE,3 GTs may be relatively small, as with the ManE specific E1,3 GlcNAcTs Bre-5 
and Brainiac (number 27 and 31 in Figure 23), or high, as exemplified by the Fringe family of 
orthologues (numbers 15 to 18 in Figure 23). Furthermore, protein mutant analysis for E1,3
GlcAT-I showed, that the determinants for its donor specificity were located to mostly non-
conserved regions close to the C-terminus of the catalytic domain (47). For example, the 
substitution of a single amino acid at the C-terminus broadened the donor specificity of the 
enzyme considerably from UDP-GlcA to include the nucleotide sugars UDP-Glc, UDP-GlcNAc 
and (non-physiological) UDP-Man. It is therefore difficult to predict, which substrates are 
preferred and the determination of the specificities of a GT remains “wet” biochemistry.  
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GlcNAc 1,3FucE D
? 1,3?E
GlcNAc 1,3ManE E
GlcNAc 1,3GalE E
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GlcA 1,3GalE E
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      30
GlcNAc 1,3ManE E
? 1,3?E
Figure 22: ClustalW Tree (62) with sequences of putative and established E1,3 GTs of D.
melanogaster and other species. yellow: non-D. melanogaster GTs with established donor and 
acceptor specificities, red: D. melanogaster GTs with established specificities, white: expressed 
isoforms w/o assigned activities [III], grey: unpublished. Sequences (accession number): 1: CG8668, 
2: CG8673, 3: CG30036, 4: CG33145, 5: CG33037, 6: hE3GalT6 (NP_542172), 7: CG8734, 8:
CG9520, 9: CG8708, 10: hC1E3GalT (AAF81981), 11: CG13904-1, 12: CG2975, 13: CG2983, 14:
CG7440, 15: rradical fringe (Q9R149), 16: clunatic fringe (O12971), 17: zfmanic fringe 
(AAT46070), 18: FRG, 19: hGlcAT-1 (O94766), 20: CG32775, 21: CG3881, 22: CG6207, 23:
CG18558, 24: CG3119, 25: mE3GnT5 (NP_114436), 26: hE3GalT5 (Q9J167), 27: BRN, 28:
CG11357, 29: CG3038, 30: mE3GalNAcT-II (BC029564), 31: celbre-5 (NP_741492). Prefixes as 
follows: zf: zebra fish, m: mouse, r: rat, h: human, c: chicken, cel: C. elegans, for D. melanogaster
sequences c.f. Table 6 on the next page. 
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10 Abbreviations
GT: glycosyltransferase, Gal: Galactose, GalT: galactosyltransferase, GlcNAc: N-
acetylglucosamine, GlcNAcT: N-acetylglucosaminyltransferase, GalNAc: N-
acetylgalactosamine, Fuc: Fucose, Glc: Glucose, IdoA: Iduronic acid, GlcA: Glucuronic acid, 
Dolichylphosphomannose: DolP-Man, Dolichylphosphoglucose: DolP-Glc, DolPP: 
dolichylpyrophosphate, GAG: glycosaminoglycan, CS: chondroitin sulfate, HS: heparan sulfate, 
GSL: glycosphingolipid, Cer: Ceramide, GlcCer: Glucosylceramide, MacCer: Mactosylceramide, 
pEtn: phosphoethanolamine, PC: phosphocholine, pEtnT: phosphoethanolamine transferase, 
GPI-anchor: glycosylphosphatidylinositol anchors, Nz: neutral zwitterionic (contains 1 pEtn 
residue), Nz2: neutral doubly zwitterionic (contains 2 pEtn residues), Az: acidic zwitterionic, 
EGFR epidermal growth factor receptor, TSP: thrombospondin 1, ppGalNAcT: polypeptide N-
acetylgalactosaminyltransferases. 
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Mutations at the Drosophila melanogaster brainiac
locus lead to defective formation of the follicular epithe-
lium during oogenesis and to neural hyperplasia. The
brainiac gene encodes a type II transmembrane protein
structurally similar to mammalian 1,3-glycosyltrans-
ferases. We have cloned the brainiac gene from D. mela-
nogaster genomic DNA and expressed it as a FLAG-
tagged recombinant protein in Sf9 insect cells.
Glycosyltransferase assays showed that brainiac is cap-
able of transferring N-acetylglucosamine (GlcNAc) to
-linked mannose (Man), with a marked preference for
the disaccharide Man(1,4)Glc, the core of arthro-series
glycolipids. The activity of brainiac toward arthro-se-
ries glycolipids was confirmed by showing that the en-
zyme efficiently utilized glycolipids from insects as ac-
ceptors whereas it did not with glycolipids from
mammalian cells. Methylation analysis of the brainiac
reaction product revealed a 1,3 linkage between
GlcNAc and Man, proving that brainiac is a 1,3Glc-
NAc-transferase. Human 1,3GlcNAc-transferases
structurally related to brainiac were unable to trans-
fer GlcNAc to Man(1,4)Glc-based acceptor substrates
and failed to rescue a homozygous lethal brainiac al-
lele, indicating that these proteins are paralogous and
not orthologous to brainiac.
The importance of glycoconjugates in regulating develop-
mental processes is continually being supported by studies
performed in various model organisms like Caenorhabditis el-
egans (1), Drosophila melanogaster (2), and the mouse (3). The
Drosophila genes sugarless, sulfateless, pipe, tout-velu, and
dally participate in the formation of proteoglycans. Loss of
function mutations in some of these genes produce polarity
phenotypes mechanistically connected to incorrect diffusion of
the signaling proteins wingless and hedgehog (4–6). The ro-
tated abdomen locus, whose disruption is associated with a
helical rotation of the body, has been found to encode a poten-
tial O-mannosyltransferase (7), and fringe, which modulates
the interaction of the Notch receptor with its ligands (8), has
recently been demonstrated to be a 1,3N-acetylglucosaminyl-
transferase (GlcNAcT)1 (9, 10).
The Drosophila gene brainiac (brn) (11) encodes a protein
that shares structural motifs with 1,3glycosyltransferases
(12, 13). The brn gene is localized on the X chromosome. brn
was shown to cooperate with the epidermal growth factor re-
ceptor and one of its ligands, the Drosophila TGF homologue
gurken (11) during oogenesis. Mutant brn alleles exhibit al-
tered morphology of the follicular epithelium (11), female ste-
rility (14), and germ line loss (15). Furthermore, brn embryos
develop neural hyperplasia and epidermal hypoplasia (11) as
encountered with Notch hypomorphic alleles and other neuro-
genic mutants, suggesting implications of brn in Notch signal-
ing (16, 17).
While the relationships between brn and specific signaling
pathways have been examined genetically, the nature of these
interactions remained elusive as long as the biochemical func-
tion of brn was unclear. In the present study, we show that brn
has a 1,3N-acetylglucosaminyltransferase (GlcNAcT) activity
directed toward the Man(1,4)Glc core structure of arthro-
series glycolipids.
EXPERIMENTAL PROCEDURES
Cloning and Expression—The brn gene was amplified by PCR from
D. melanogaster OregonR genomic DNA during 30 cycles at 95 °C for
45 s, 55 °C for 30 s, 72 °C for 60 s using the primers 5-TTTGGATCC-
GTCGCCATGCAAAGT-3 and 5-CCTGTTCTAGATGCTACGCGTAA-
T-3. The resulting 1.0-kb fragment was digested with BamHI and XbaI
and subcloned into the pFastbac-FLAG(a) vector (Invitrogen) linearized
at the BamHI and XbaI sites. The FLAG-tagged brn gene was ex-
pressed as a recombinant baculovirus in insect cells as described pre-
viously (13). Infected cells (107) were lysed at 72 h post-infection in 600
l of 50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, and a
protein inhibitor mixture (complete, EDTA free, Roche Diagnostics) on
ice. Post-nuclear supernatants were incubated with 240 l of anti-
FLAG M2-agarose beads (Sigma) under rotation for 2.5 h at 4 °C. Beads
were washed three times with Tris-buffered saline and used as enzyme
source for assays.
Glycosyltransferase Assays—All donor and acceptor substrates were
from Sigma except Man(1,4)Glc(1-OpNP) (pNP  p-nitrophenyl),
which was purchased from Toronto Research (North York, Canada).
Glycosyltransferase activity was assayed for 60 min at 25 °C with 15 l
of beads, 5% Me2SO, 20 mM MnCl2, 0.08 mM UDP-GlcNAc including 5
104 cpm of UDP-[14C]GlcNAc (Amersham Biosciences), and various
acceptors (see Table I). Reaction products were purified over C18 Sep-
Pak cartridges (Waters) (18) and quantified in a Tri-Carb 2900TR liquid
scintillation counter (Packard) with luminescence correction.
Glycolipid Extraction—D. melanogaster Schneider 2 cells, Spodopt-
era frugiperda Sf9 cells, and human colon carcinoma Caco-2 cells were
washed three times in phosphate-buffered saline and extracted in iso-
propanol:hexane:H2O (55:25:20). Extracts were spun twice at 500 x g,
and supernatants were dried under N2. Phospholipids were removed by
saponification in 0.2 M NaOH in methanol for 24 h at 37 °C. After
neutralization with HCl, the extracts were expanded to theoretical
upper phase (methanol:water:chloroform, 47:48:3), applied on C18 Sep-
* This work was supported by Swiss National Science Foundation
Grant 631-062662.00 (to T. H.). The costs of publication of this article
were defrayed in part by the payment of page charges. This article must
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Pak cartridges, and eluted with 5 ml of methanol. Eluates were dried
under N2 and resuspended in 500 l of methanol. The procedure yielded
about 120 g of mannose equivalents for 108 S2 and Sf9 cells and 20 g
of mannose equivalents from 107 Caco-2 cells as determined by the
phenol sulfuric acid assay (19).
Thin-layer Chromatography (TLC)—Glycolipids (5 g of mannose
equivalents per assay) were dried under N2 and incubated together
with 10 l of beads-bound enzyme in 50 l of 50 mM cacodylate buffer,
pH 7.1, 20 mM MnCl2, 0.06% Triton X-100, 2.5  10
4 cpm of UDP-
[14C]GlcNAc for 90 min at 25 °C. Reaction products were expanded to
theoretical upper phase and purified over C18 Sep-Pak cartridges as
described above. After drying over N2, the eluates were taken up in 100
l of methanol:chloroform (1:1) and separated on aluminum high-per-
formance thin-layer chromatography plates (Merck, Darmstadt, Ger-
many) using a solvent system of chloroform:methanol:0.25% CaCl2 (5:
4:1). Plates were stained with orcinol sulfuric acid (Sigma). The
[14C]GlcNAc(1,3)Gal(1,4)Glc-ceramide (Lc3) standard was produced
enzymatically with the Lc3 synthase 1,3 GlcNacT protein (20) using
Gal(1,4)Glc-ceramide (Lc2) (Sigma) as acceptor substrate.
brn Complementation in Drosophila—Human 3GnT1 (21), 3GnT4
(22) and 3GnT5 (20) cDNAs and the Drosophila brn gene were sub-
cloned into the pUAST vector (23). The rescue constructs pUAST-
3GnT1, pUAST-3GnT4, pUAST-3GnT5, and pUAST-brn were in-
jected together with the pUChsp2–3 P-element helper plasmid
(Flybase accession FBmc0000938) into yellow white Drosophila em-
bryos using standard procedures. Then, white progeny was selected
and X-chromosomal insertions of the transgene excluded. The GAL4
lines, driving ubiquitous expression of the UAS-transgenes in an arma-
dillo pattern (24), carry Bloomington Stock numbers 1560 and 1561.
Males of the genotype yellow white/Y; transgene/ were mated to vir-
gins forked brn1.6P6/FM6-w1; 1560 GAL4/ and forked brn1.6P6/FM6-w1;
1561 GAL4/ and the progeny examined for males carrying the forked
mutation for 8 days after eclosion of the first flies. At least two inde-
pendent lines of each transgene were used for the complementation
assay, which were repeated four times.
Structural Analysis—A mixture of substrate and of 10 nmol of prod-
uct was separated by reversed phase HPLC on a 3  250 mm column
filled with 5 M ODS Hypersil (Shandon) at a flow rate of 0.6 ml/min.
The column was eluted with a linear gradient from 6 to 24% of methanol
during 18 min in 0.1 M ammonium acetate, pH 4.0. p-Nitrophenylgly-
cosides were monitored at 245 nm. The mixture was also analyzed after
incubation with N-acetyl--hexosaminidase from jack beans (Sigma)
(25). The fraction of interest was collected in a screw capped glass vial
and dried in a speed-vac concentrator. A small aliquot was used for
matrix assisted laser desorption mass spectrometry as described else-
where (25). The sample was dried over phosphorus pentoxide in vacuo
and permethylated using NaOH (26). Partially permethylated alditol
acetates were prepared using NaBD4 as the reducing agent and ana-
lyzed by gas chromatography/mass spectrometry using a 60 m SP2330
(Restek) (27) and a Finnigan Ion Trap ITD800. Derivatives of terminal
and 3-substituted galactose served to compare retention times with the
data given by Doares et al. (27).
RESULTS
We have cloned the D. melanogaster brn gene by PCR am-
plification and expressed it as an N-terminally FLAG-tagged
full-length protein in Sf9 insect cells. The recombinant brn
protein was bound to anti-FLAG-agarose beads, and cellular
contaminants such as possible endogenous acceptor substrates
were washed out before assaying for enzymatic activity. A
GlcNAcT activity was only detected toward the Man(1-OpNP)
acceptor when monosaccharide substrates were assayed (Table
I). Highest activity was measured toward the disaccharide
acceptor Man(1,4)Glc(1-OpNP), whereas a slight activity
was also detected toward Gal(1,4)Glc(1-OpNP) (Table I). The
Man(1,4)Glc structure represents the core of arthro-series
glycolipids found in nematodes (28) and insects (29) among
others.
In Drosophila, the arthro-series Man(1,4)Glc core is elon-
gated with a 1,3-linked GlcNAc (30), suggesting that brn may
represent the enzyme catalyzing this step. To test this hypoth-
esis, we have isolated neutral glycolipids from Drosophila S2
and Spodoptera Sf9 cells and assayed these glycolipids as ac-
ceptors for the anti-FLAG beads-bound brn enzyme. A signifi-
cant GlcNAc-transferase activity was detected when incubat-
ing brn together with insect glycolipids, whereas only a low
activity was measured with glycolipids extracted from mam-
malian Caco-2 cells, likely reflecting the low specificity of brn
for lactosylceramide. The reaction products were separated by
TLC and plates were autoradiographed, revealing a [14C]Glc-
NAc-labeled band at the size of a trihexoside ceramide in S2
and Sf9 cells (Fig. 1).
The nature of the linkage between GlcNAc and the underly-
ing -linked Man residue was investigated by methylation
analysis of the brn reaction product GlcNAc-Man(1-OpNP). In
reversed phase HPLC, the presumed disaccharide product
eluted slightly ahead of the substrate Man(1-OpNP). The
disaccharide peak disappeared upon incubation with N-acetyl-
-hexosaminidase (Fig. 2A). The purified fraction correspond-
ing to the disaccharide peak exhibited a pseudomolecular ion of
m/z 513.5. Linkage analysis of the GlcNAc-Man(1-OpNP) di-
saccharide product gave a peak at the relative retention time of
0.597, which suggests a 2- or a 3-substituted mannosyl residue
(27). The fragment spectrum clearly identified the derivative as
substituted in the 3-position (Fig. 2B), thus confirming the
identity of brn as a 1,3 GlcNAcT.
The brn protein is structurally related to human 1,3 glyco-
syltransferase enzymes (12, 13). The acceptor specificity of brn
for the arthro-series glycolipid core suggested that it represents
a paralogous enzyme to the mammalian 1,3 glycosyltrans-
ferases, including 1,3 galactosyltransferases (13, 31, 32), 1,3
GlcNAcT (20, 22), and a 1,3-N-acetylgalactosaminyltrans-
ferase (33) acting on GlcNAc-, Gal-, and GalNAc-based
acceptors. Although no mammalian 1,3 GlcNAcT has been
described to act on -linked Man acceptors, we have investi-
gated whether the three human 1,3 GlcNAcT structurally
closest to brn can complement the lethal phenotype of brn
deficient Drosophila flies. To this end, we have expressed the
human 3GnT-I (21), -IV (22), and -V (20) in brn1.6P6 mutant
flies (34) using the UAS-GAL4 transgenesis system (23).
The human 3GnT transgenes and a brn transgene were
expressed in flies carrying the allele brn1.6P6, which causes
lethality at the late pupal stage. The transgenes were ex-
pressed ubiquitously using armadillo GAL4 transactivator
lines. The brn transgene did rescue brn1.6P6 mutant males from
their hemizygous late pupal lethality, whereas the human
3GnT transgenes did not (Table II). The rescue of brn1.6P6
males was confirmed by detection of the forked marker, whose
gene is located besides the brn1.6P6 allele on the X chromosome.
Control crosses of females carrying brn1.6P6 with yellow white
males did not yield any living brn1.6P6 forked/Y males either.
The inability of human 3GnT enzymes to compensate for the
TABLE I
Acceptor substrate specificity of brn
Acceptor substrate (20 mM) Mocka brnb
pmol/min/ml
Glc(1-OpNP) 7.2 5.2
Glc(1-OpNP) 5.4 5.7
Gal(1-OpNP) 8.4 11.1
Gal(1-OpNP) 6.2 12.6
GalNAc(1-OpNP) 6.7 7.2
GalNAc(1-OpNP) 5.3 8.9
Fuc(1-OpNP) 7.6 4.3
Fuc(1-OpNP) 6.6 5.5
Man(1-OpNP) 4.6 16.1
Man(1-OpNP) 5.6 400.0
Man(1,4)Glc(1-OpNP) 3.0 855.1
Gal(1,4)Glc(1-OpNP) 4.5 24.9
a Anti-FLAG bead bound lysate from Sf9 cells infected with mock
baculovirus.
b Anti-FLAG bead bound lysate from Sf9 cells infected with brn
baculovirus.
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loss of brn activity in mutant flies suggested that the former
enzymes cannot elongate the arthro-series glycolipid core in
vivo. This was confirmed in vitro by showing that the human
3GnT enzymes did not exhibit significant activity toward the
Man(1,4)Glc(1-OpNP) acceptor (Table II).
DISCUSSION
We have shown that Drosophila brn, a member of the 1,3
glycosyltransferase family, encodes a 1,3 GlcNAcT enzyme
with a specificity for the Man(1,4)Glc disaccharide found in
arthro-series glycolipids (29). Several mammalian enzymes
structurally related to brn have been suggested to represent
homologues (35–37). However, the specificity of brn for
Man(1,4)Glc, a disaccharide that has never been described in
vertebrates, rather indicates that brn and mammalian 1,3
glycosyltransferases are paralogous proteins derived from a
common ancestor gene.
The functional disparity between the 1,3 GlcNAcT brn and
mammalian 1,3 GlcNAcT enzymes is further supported by the
inability of the latter to complement the lethal phenotype of the
mutant allele brn1.6P6 in Drosophila. The specificity of brn
toward Man1,4Glc-Cer suggests the presence of functional
homologues only in organisms harboring arthro-series glycolip-
ids, whose core structure is GlcNAc(1,3)Man(1,4)Glc-Cer. A
protein structurally related to brn has recently been described
in C. elegans (38), which express arthro-series glycolipids (28).
The loss of that gene, named bre-5 (39), renders the animal
resistant to high doses of Bacillus thuringiensis Bt toxin. Since
Bt toxin binds to arthro-series glycolipids (40), it is possible
that bre-5 participates in the formation of this class of glyco-
lipids in C. elegans and thereby represents a true orthologue of
brn.
brn mutations affect follicle cell-germ line interactions and
lead to neurogenic phenotypes in Drosophila embryos. Consid-
ering the involvement of brn in glycolipid biosynthesis, one can
envision that arthro-series glycolipids may regulate cell adhe-
sion, proliferation, and differentiation via carbohydrate-lectin
interactions. On the other hand, arthro-series glycolipids may
modulate specific signaling proteins in a way similar to gan-
gliosides affecting the epidermal growth factor receptor (41,
42), insulin receptor (43), and platelet-derived growth factor
receptor (44) signaling cascades. The notion that brn glycolipid
products interact with adhesion or signaling proteins implies
FIG. 1. TLC separation of brn-modified glycolipids. The top
panel shows a plate stained with orcinol reagent and the bottom panel
the autoradiogram of the same plate. brn-bound beads (brn) or beads
preincubated with mock-infected Sf9 cells (mock) were incubated with
neutral glycolipids from Drosophila S2 cells (S2), Spodoptera Sf9 cells
(Sf9), human Caco-2 cells (Caco), or without added glycolipids (no GL).
The neutral glycolipid standard (GL Std) contained: Gal-Cer;
Gal(1,4)Glc-Cer (Lc2); Gal(1,4)Gal(1,4)Glc-Cer (Gb3); Gal(1,4)
Gal(1,4)Glc-Cer (Gb4), and GalNAc(1,3)GalNAc(1,3)Gal(1,4)Glc-
Cer (FS). Lc2/Lc3, Lc2 was elongated to Lc3 by incorporation of [14C]
GlcNAc catalyzed by the human 3GnT-V enzyme (20).
FIG. 2. Structural analysis of brn product. A, HPLC separation of
product and substrate of 1,3GlcNAcT brn. p-Nitrophenyl--D-man-
nopyranoside was incubated with brn in the presence of UDP-GlcNAc.
The mixture was prepurified over Sep-Pak C18 cartridges and subjected
to reversed phase chromatography (trace a). A small product peak (P)
eluted ahead of the substrate (S). The product disappeared upon incu-
bation with -N-acetylhexosaminidase (trace b) which indicates it to
contain a -linked GlcNAc residue. B, methylation analysis of p-nitro-
phenyl disaccharide. The electron impact mass spectrum of the par-
tially methylated monodeuterated alditol acetate derived from the man-
nosyl residue of the disaccharide product shows several fragments
indicative of a substitution in position 3 as depicted by the insert.
Especially the presence of mass 118 and the absence of mass 190
exclude a 2-substitution, which could not be ruled out from the reten-
tion time alone (27).
TABLE II
Complementation of Drosophila brn1.6P6
Rescue of the brn1.6P6 late pupal lethal phenotype by ubiquitous
expression of Drosophila brn and human 1,3GlcNAcT transgenes.
1,3GlcNAcT genea Linesb brn
1.6P6
rescuec
GlcNAc-Man(1,4)Glc
activityd
%
Drosophila brn 2 2 100
Human 3GnT-I 2 0 6.3
Human 3GnT-IV 2 0 1.6
Human 3GnT-V 6 0 8.6
a 3GnT-I (21), 3GnT-IV (22), and 3GnT-V (20).
b Number of independent lines per transgene tested.
c Number of independent lines per transgene rescueing brn1.6P6 (34).
Rescue was scored by counting males alive with a forked phenotype
within 8 days after eclosion of control animals.
d In vitro GlcNAc-transferase activity towards Man(1,4)Glc(1-
OpNP) given in percentage of the activity measured with brn.
Brainiac Is a 1,3GlcNAc-transferase 32419
that other mutant genes with phenotypes similar to those
encountered in brn mutant flies may encode partner lectin/
signaling proteins. Along this line, Drosophila egghead mu-
tants have similar and non-additive phenotypes to brn (17).
Experiments aimed at characterizing the biochemical and func-
tional relation between brn products and the egghead protein
should reveal the mechanisms how arthro-series glycolipids
regulate morphogenic events during Drosophila development.
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Crystal (Cry) proteins made by the bacterium Bacillus
thuringiensis are pore-forming toxins that specifically
target insects and nematodes and are used around the
world to kill insect pests. To better understand how
pore-forming toxins interact with their host, we have
screened for Caenorhabditis elegans mutants that resist
Cry protein intoxication. We find that Cry toxin resist-
ance involves the loss of two glycosyltransferase genes,
bre-2 and bre-4. These glycosyltransferases function in
the intestine to confer susceptibility to toxin. Further-
more, they are required for the interaction of active
toxin with intestinal cells, suggesting they make an oli-
gosaccharide receptor for toxin. Similarly, the bre-3 re-
sistance gene is also required for toxin interaction with
intestinal cells. Cloning of the bre-3 gene indicates it is
the C. elegans homologue of the Drosophila egghead
(egh) gene. This identification is striking given that the
previously identified bre-5 has homology to Drosophila
brainiac (brn) and that egh-brn likely function as con-
secutive glycosyltransferases in Drosophila epithelial
cells. We find that, like in Drosophila, bre-3 and bre-5 act
in a single pathway in C. elegans. bre-2 and bre-4 are also
part of this pathway, thereby extending it. Consistent
with its homology to brn, we demonstrate that C. elegans
bre-5 rescues the Drosophila brn mutant and that BRE-5
encodes the dominant UDP-GlcNAc:Man GlcNAc trans-
ferase activity in C. elegans. Resistance to Cry toxins has
uncovered a four component glycosylation pathway that
is functionally conserved between nematodes and in-
sects and that provides the basis of the dominant mech-
anism of resistance in C. elegans.
Bacterial pore-forming toxins that damage membranes are
important virulence factors associated with pathogenic bacte-
ria (1, 2). Examples include aerolysin from Aeromonas hy-
drophila,  toxin from Staphylococcus aureus, hemolysin from
Escherichia coli, and main family crystal (Cry)1 proteins from
Bacillus thuringiensis. Of these, Cry proteins are unique in
that they specifically target invertebrates (insects and nema-
todes) and are generally considered innocuous to mammals.
Mammalian resistance to Cry toxins is thought to be due to
toxin insolubility, lack of proper proteolytic processing, and
lack of proper receptors in the mammalian gut (3). As such, Cry
proteins demonstrate a degree of safety toward vertebrates
that is unmatched by any other pest control product and are
used extensively around the world in the control of insect pests
that damage crops and carry disease.
We previously reported on the isolation of Caenorhabditis
elegans bre mutants (for Bt-toxin resistant) that resist Bt Cry
protein intoxication (4). When fed the main family crystal pro-
tein Cry5B either as protein crystals or as E. coli produced
protein, C. elegans becomes rapidly sick and shows degenera-
tion of the intestine, loss of coloration, inhibition of growth,
inhibition of progeny production, and eventual death (4, 5).
Cry5B-resistant bre mutants were isolated among the F2 prog-
eny of ethylmethanesulfonate mutagenized larvae. After
screening 42,000 mutagenized haploid genomes for animals
resistant to Cry5B, we isolated 14 alleles of bre-2, 19 alleles of
bre-3, 9 alleles of bre-4, and 2 alleles of bre-5 (4).2 All are
strongly resistant to the pore-forming toxin, and all are healthy
in the absence of toxin as well. To date we have also isolated
one allele of bre-1 that has significantly weaker resistance to
Cry5B (4). No other loci have been identified in these screens.
Thus, strong, healthy resistance to the pore-forming toxin in-
evitably leads to mutation of bre-2, bre-3, bre-4, or bre-5. The
identification of bre-5 as a 1,3-glycosyltransferase gene has
been reported (6).
To our knowledge this approach is unique in its objective to
genetically characterize how whole animals interact with and
resist a bacterial pore-forming toxin. In the case of Cry pro-
teins, identifying the genes that mutate to confer resistance is
important since the major threat to the long term utility of
insecticidal Cry proteins is the emergence of resistance. More
generally, understanding the pathways that can mediate re-
sistance might suggest therapeutic strategies for coping with
bacterial toxins that target mammals.
Here, we identify the Cry5B toxin resistance genes bre-2 and
bre-4 as glycosyltransferase genes that previously have not
* This work was funded by National Science Foundation Grant MCB-
9983013 and grants from the Burroughs-Wellcome Foundation and the
Beckman Foundation (to R. V. A.) and by National Institutes of Health
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been genetically characterized. We find that bre-2 and bre-4
function in the intestine to confer susceptibility to Cry5B and
are also required for the interaction of toxin with intestinal
cells in vivo. We also identify the bre-3 resistance gene as
sharing significant homology to Drosophila egghead (egh). Be-
cause bre-5 shares sequence similarity to the Drosophila brai-
niac (brn) gene and since egh and brn function in a single
pathway in Drosophila, we hypothesized that the Cry protein
intoxication pathway in C. elegans is equivalent to the Dro-
sophila pathway. We indeed show that bre-3 and bre-5 function
in a common pathway in C. elegans, that bre-2 and bre-4 are
also part of this pathway, and that the C. elegans bre-5 gene
has the same in vivo and in vitro activities as Drosophila brn.
EXPERIMENTAL PROCEDURES
C. elegans Culture and Microscopy—C. elegans was propagated using
standard techniques with strain Bristol N2 as the wild type (7). All
nematode assays were carried out at 20 °C. For microscopy of live
animals, nematodes were mounted on pads consisting of 2% agarose
and 0.1% sodium azide. Low magnification microscopy was carried out
on an Olympus BX-60 microscope using a 10 objective coupled to a
0.5 camera mount and a DVC camera. Endocytosis assays were im-
aged and deconvolved using a DeltaVision system (Applied Precision)
on an Olympus IX-70 microscope using a 40 objective (NA1.35) and
differential interference contrast or fluorescence optics. Immunofluo-
rescence images were captured on the DeltaVision system using a 40
or 100 objective (NA1.35) and differential interference contrast or
fluorescence optics.
Cloning of bre Genes—bre-2(ye31) was placed in trans to dpy-18(e364)
unc-64(e246). 25/25 Dpy nonUncs segregated bre-2(ye31), and 23/23
Unc nonDpys segregated bre(). The deficiency eDf2 also failed to
complement bre-2(ye31), suggesting that bre-2 resided between unc-64
and the right breakpoint of eDf2. The bre-2(ye71) allele was generated
by mutagenesis in the Hawaiian strain background (CB4856) and then
placed in trans to unc-25(e156) bli-5(e518). Unc nonDpy and Dpy non-
Unc recombinants were used to follow the segregation of single nucle-
otide polymorphisms, which indicated that bre-2 mapped between nu-
cleotides 3,645 and 153,209 of Y39E4B. This region contains 14
predicted open reading frames (ORFs). Sequencing of cDNAs isolated
from two bre-2 alleles indicated that both alleles contained point mu-
tations in Y39E4B.9. Identification of the putative glycosyltransferase
Y39E4B.9 as bre-2 was confirmed by reproducing the phenotype using
RNA-mediated interference (data not shown) and by cDNA rescue from
a bre-2 mutant. Analogous to bre-3 (below, including spliced leader 1
primer at the 5 end), a complete bre-2 cDNA was constructed using
reverse-transcribed RNA from wild-type nematodes. The predicted
amino acid sequence is exactly as predicted for Y39E4B.9.
bre-4(ye13) was placed in trans to unc-35(e259) dpy-5(e61). 29/32 Dpy
nonUncs-segregated bre-4(ye13) indicated bre-4 was near and to the
right of unc-35. Bre nonDpy recombinants from bre-4(ye13) dpy-5(e61)/
CB4856 heterozygotes placed bre-4 to the right of the single nucleotide
polymorphism Y71G12B.60148. Dpy recombinants from heterozygotes
unc-35(e259) dpy-5(e61),bre-4(ye43) (bre-4 allele in the Hawaiian back-
ground) placed bre-4 to the left of single nucleotide polymorphism
Y92H12A.28829. The 150-kilobase region between these boundary sin-
gle nucleotide polymorphisms contains 20 predicted ORFs. Sequencing
of cDNA isolated from the bre-4 alleles revealed changes in the enzy-
matically characterized glycosyltransferase Y73E7A.7 (8). cDNA rescue
of a bre-4 mutant confirmed the identity of bre-4. A complete cDNA was
assembled as for the other bre genes (including using spliced leader
1-specific primers). The predicted protein sequence corresponds exactly
as predicted for ORF Y73E7A.7.
bre-3(ye28) was placed in trans to sma-2(e502) ced-7(n1892) unc-
69(e587). Of 25 Sma non-Unc recombinants, 12 were sma-2(e502) bre-
3(ye28) ced-7(), 12 were sma-2(e502) bre-3() ced-7(n1892), and 1 was
sma-2(e502) bre-3() ced-7(). These data indicated bre-3 was close and
to the left of ced-7. We co-injected bre-3(ye28) animals with cosmids in
this region and plasmid pRF4, which encodes the dominant rol-6
marker, and found that 2/2 stably transmitting lines containing cosmid
B0464 were rescued to toxin susceptibility. Subcloning and injection of
different regions within B0464 indicated that the rescuing activity (8/8
lines) was conferred by a 4.3-kilobase FspI-NheI fragment containing
nucleotides 13,437–17,729. This fragment contains a single predicted
ORF B0464.4 and an additional 800 bases at both the 5 and 3 ends
of the ORF. Sequencing of genomic DNA and cDNA from three bre-3
mutant alleles indicated these alleles contained alterations in this ORF,
confirming the identity of the gene. A complete wild-type cDNA was
assembled and sequenced from two overlapping fragments generated 1)
at the 5 end by using random-primed total cDNA, a spliced leader 1
primer, an internal primer, and PCR and 2) at the 3 end by using a 
phage cDNA library (generously provided by Robert Barstead), a 3
end-specific vector primer, an internal primer, and PCR. The predicted
protein sequence from this assemble cDNA corresponds exactly to that
of the predicted B0464.4 ORF. Transmembrane domains in BRE-3 and
other related proteins were predicted using TMHMM2.0.
Intestine-specific Expression and Rescue—pBluescript (KS) (Strat-
agene) was used as the vector backbone for test constructs. The cpr-1
promoter (9), corresponding to nucleotides 9,541–11,581 of cosmid
C52E4, was amplified from C. elegans genomic DNA and cloned up-
stream of bre gene coding regions (for bre-2, bre-3, and bre-5, respec-
tively, nucleotides 66,617–69,835 of Y39E4B, 14,285–16,925 of B0464,
and 22,694–23,958 of cosmid T12G3; the bre-4 coding region was am-
plified from C. elegans cDNA). Coding regions were fused in-frame to a
double HA tag at their 3 ends, with a downstream transcription ter-
mination region derived from the bre-5 locus (T12G3 nucleotides
21,578–22,699), except in the bre-3 construct, which contained the bre-3
transcription termination region downstream of the HA tag (B0464
nucleotides 13,437–14,287).
Constructs were co-injected with the dominant rol-6 marker (pRF4)
into mutant animals to obtain stably transmitting lines carrying ex-
trachromosomal arrays. Eggs laid by Roller (or N2 control) hermaph-
rodites were placed on modified ENG agar plates containing 1 mM
isopropyl -D-thiogalactoside and 50 g/ml carbenicillin and spread
with E. coli cells expressing Cry5B (5) or with vector-only cells. Eggs
were allowed to hatch and grow for 72 h, and resistance was scored
based on the ability of larvae to progress to adulthood during the course
of the experiment. For each construct tested at least two independent
transgenic lines were assayed, and all lines possessed the reported
phenotypes with 90% penetrance, with 20 rollers and 20 non-rollers
tested per line.
Fixation and Staining for Immunofluorescence Microscopy—The fix-
ation procedure was a modification of that of Finney and Ruvkun (10).
A mixed population of a rescuing line expressing cpr-1::bre-5::2XHA or
cpr-1::bre-3::2XHA was suspended in phosphate-buffered saline, 25%
methanol, 3% formaldehyde and flash-frozen. After thawing under tap
water worms were incubated on ice for 30 min followed by 2 washes in
50 mM sodium borate buffer, 0.01% Triton X-100, pH 9.5 (BO3T). Worms
were then incubated for 20 min in BO3T plus 10 mM dithiothreitol
followed by another wash in BO3T and a 20-min incubation in BO3T
plus 0.3% hydrogen peroxide. Fixed and permeabilized worms were
then washed in phosphate-buffered saline, 0.5% bovine serum albumin,
0.05% Triton X-100, 0.02% sodium azide (antibody buffer). For staining,
all steps were carried out in antibody buffer using monoclonal anti-HA
antibodies (16B12, Covance), and a final wash included 4,6-diamidino-
2-phenylindole for DNA staining.
Assays for Endocytosis of Rhodamine-labeled Cry5B—Cry5B pro-
toxin was purified as described previously (6) and labeled using a 5-fold
molar excess of NHS-rhodamine. Trypsinization was carried out at a
1:200 (trypsin:toxin) mass ratio for 2 h at 25 °C. Trypsinized toxin was
still toxic but 5–10-fold less based on growth assays. We used Edman
degradation sequencing and determined that trypsin removes the first
170 amino acids, which includes predicted  helix 3 but not helix 4.
Consistent with our results studies with insecticidal Cry toxins show
that  helices 4 and 5 are critical for toxin function and that helices 1–3
may contribute some activity (11, 12). Based on the apparent molecular
weight of trypsinized toxin, trypsin is predicted to remove most of the
carboxyl-terminal protoxin domain. Animals (L4 stage) were incubated
in M9 medium containing 50 g/ml protoxin or 120 g/ml trypsinized
toxin for 3 h and washed 3 times in M9 before imaging. For wash-out
experiments, bre-4(ye13) and bre-5(ye17) animals fed rhodamine toxin
for a few hours in wells were pipetted onto standard NG plates and
examined every few minutes on an Olympus green fluorescent protein
dissecting scope fitted with a rhodamine filter.
Single Mutant Versus Double Mutant Resistance Assays—All double
mutants were constructed and confirmed using a similar strategy. For
example, the bre-4(ye13),bre-5(ye17) double mutant was created by mat-
ing bre-4(ye13) males into the strain dpy-5(e61),bre-5(ye17) (bre-4 and
dpy-5 are both on chromosome I). NonDpy F1 progeny were cloned, and
in the F2 nonDpy Cry5B-resistant animals were picked that segregated
F3 Dpy (bre-4(y13),dpy-5(e61),bre-5(ye17)). NonDpy F3 were cloned out,
and those that did not segregate Dpy were selected as bre-4(ye13),bre-
5(ye17) putative doubles. The presence of both mutations was verified
by sequencing DNA.
To measure resistance of single and double mutants we used the
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Cry5B-related crystal protein Cry14A (5, 6). Cry14A is required for
these studies since bre-2, -3, -4, and -5 are very highly resistant to
Cry5B (e.g. they are not killed by even 1 mg/ml Cry5B) but are only
moderately resistant to Cry14A. Cry14A was produced in E. coli and
incorporated into the assay diet as described (6). Assays were carried
out in 24-well plates, with each well containing 400 l of S medium with
30 g/ml each of tetracycline and chloramphenicol and 60 newly
hatched L1 animals, with a final bacterial density of A600  0.25. After
a 60-h exposure at 20 °C, animals were mounted and imaged, and area
measurements were made outlining the nematodes by hand and proc-
essing with NIH Image.
bre-5 Rescue of the Drosophila brainiac Mutant—The bre-5 cDNA
was cloned into pUAST (13) and used to transform yellow, white em-
bryos using standard techniques. Two independent lines containing the
transgene on chromosome II were used for brn complementation as-
says, which were carried out as described in Mu¨ller et al. (14). Briefly,
male UAS-bre-5 transformants were crossed to females of the genotype
forked, brn1.6P6/FM6,w1, actin-, heat shock- or armadillo-GAL4,w.
Rescue was scored based on the ability of forked male progeny to hatch.
The GAL4 drivers used for this experiment carry the Bloomington stock
numbers 1560 (armadillo-GAL4), 2077 (heat-shock GAL4), and 4414
(actin-GAL4). These lines were generously provided by Markus Noll
and Erich Frei (Institute of Molecular Biology, University of Zu¨rich).
Flies carrying UAS-brainiac and UAS-3GnT-IV (a human N-acetyl-
glucosaminyltransferase) were used as positive and negative controls,
respectively.
bre-5-dependent N-Acetylglucosaminyltransferase Assays—N2 and
bre-5(ye17) mixed larval-staged animals were reared on ENG medium
(standard NG with an additional 2.5 g of peptone and 1 g of yeast
extract per liter), washed, flash-frozen in 50 mM Tris, pH 7.5, as a
0.2-ml pellet, and stored at 70 °C. Samples were sonicated on ice in
0.05% Triton-X-100, 50 mM Tris and centrifuged at 15,000  g for 10
min to obtain a clarified supernatant. The assay mixture (25 l) con-
tained 50 mM cacodylate, pH 6.5, 0.1% taurodeoxycholate, 10 mM
MnCl2, 1 Ci of UDP-[6-
3H]GlcNAc (39.7 Ci/mmol, PerkinElmer Life
Sciences),10 mM Man1,4Glc-pNP (custom synthesis of Toronto Re-
search, ON, Canada), and 8 g of extracted protein (N2 or bre-5) as the
enzyme source. After incubation at 25 °C for 7 h, the reaction products
were diluted with 0.5 ml of 0.5 M NaCl and applied to a Sep-Pak C18
cartridge (100 mg; Waters). After washing the cartridge with 25 ml of
water, the products were eluted with 50% methanol, dried, and counted
by liquid scintillation.
RESULTS
To better understand how resistance to pore-forming Cry
toxins develops, we used single-nucleotide polymorphisms to
map the bre-2 and bre-4 genes to small molecular intervals of
20 genes, each of which contained a glycosyltransferase gene.
Given that the previously identified bre-5 was shown to encode
a glycosyltransferase gene (6), we sequenced cDNAs isolated
from bre-2 and bre-4 mutant alleles and found that multiple
alleles of each were associated with point mutations in the
glycosyltransferase genes Y39E4B.9 and Y73E7A.7, respec-
tively (Fig. 1, A and B). At least one allele for each gene
(bre-2(ye68) and bre-4(ye13)) is predicted to eliminate protein
function by truncation of the putative glycosyltransferase cat-
alytic domain, indicating that Cry5B resistance is the null
phenotype for each. That RNA-mediated interference (RNAi) of
bre-2 recapitulates Cry5B resistance supports this (data not
shown). Rescue data (see below) confirm that these glycosyl-
transferase genes encode bre-2 and bre-4. Cloning and charac-
terization of bre-3, which encodes an unusual glycosyltrans-
ferase of striking resemblance to a known glycosyltransferase
in Drosophila, is dealt with below.
bre-2 encodes a putative family 31 1,3-glycosyltransferase
with a single amino-terminal membrane-spanning domain and
an appropriately positioned DXD motif that is conserved in this
enzyme family and is thought to be critical for catalysis (Fig.
1A). In general, BRE-2 shares 25% amino acid identity in its
putative enzymatic domain with other 1,3-glycosyltrans-
ferases such as with BRE-5 (a 1,3-GlcNAc transferase; see
Griffitts et al. (6) and below) and insect and mammalian 1,3-
Gal and GlcNAc-transferases. bre-2 is also a member of a more
closely related and expanded subfamily of C. elegans 1,3-
glycosyltransferase genes that includes T09F5.1, F14B6.6,
T09E11.10, E03H4.11, C54C8.3, F14B6.4, C47F8.3, C47F8.5,
C47F8.6, and T15D6.5 and to which it shares 40% identity in
its glycosyltransferase domain. To our knowledge, bre-2 is the
first one of these family members to be characterized geneti-
cally and to be demonstrated to have a loss of function
phenotype.
bre-4 is predicted to encode a member of the family 7 glyco-
syltransferases, of which 1,4-galactosyltransferases are the
best characterized (15). BRE-4 is predicted to contain a single
membrane-spanning region near its amino terminus as well as
conserved residues involved in catalysis (Fig. 1B). BRE-4
has been previously characterized biochemically as a UDP-
GalNAc:GlcNAc1,4-N-acetylgalactosaminyltransferase (Ce4
GalNAcT) (8). BRE-4/Ce4GalNAcT specifically synthesizes
the GalNAc1,4GlcNAc sequence commonly found on glycopro-
teins and glycolipids. No mutational analysis of bre-4 has been
previously reported. There are two other related glycosyltrans-
ferase genes in the C. elegans genome. Blast searches using
both BRE-4 full-length protein and its enzymatic domain indi-
cate a best hit and likely homologue in Drosophila melano-
gaster (predicted gene CG8536) and Anopheles gambiae (ORF
from nucleotides 565443 to 566142, chromosome II). The pre-
dicted catalytic domains of these proteins, respectively, share
45 and 51% identity to the BRE-4 catalytic domain.
Expression of bre-5, bre-2, and bre-4 in the Intestine Is Re-
quired for Cry Protein Intoxication—Based on the fact that Cry
toxins appear to specifically attack the gut cells of insects and
nematodes, we predicted that bre-2 and bre-4 glycosyltrans-
ferase genes should be required in intestinal cells for Cry
protein intoxication. To demonstrate this intestinal require-
ment while simultaneously confirming the correct identities of
bre-2 and bre-4, we placed wild-type bre-2 genomic coding re-
FIG. 1. bre-2 and bre-4 genes encode a putative and a known glycosyltransferase, respectively. The protein sequences shown are
assembled by translating bre-2 and bre-4 cDNAs. BRE-2 (A) and BRE-4 (B) sequences are shown. Solid underlines denote the predicted
membrane-spanning regions. Double underlines indicate conserved motifs known to play key catalytic roles in related glycosyltransferases.
Mutations observed in various alleles are also shown.
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gion and bre-4 cDNA downstream of the intestinal-specific
C. elegans promoter from the cpr-1 gene (9). As a control using
the previously cloned bre-5 gene we also made a cpr-1::bre-5
construct in which a 2 HA tag was fused in-frame at the
carboxyl terminus of bre-5. Intestine-specific expression of the
cpr-1 promoter was confirmed by HA antibody staining of a
stably transmitting line transformed with the cpr-1::bre-5:HA
construct (Fig. 2, A and B). This construct was fully capable of
restoring Cry5B susceptibility to a bre-5(ye17) mutant (Fig. 2,
C and D), demonstrating that intestinal expression of wild-type
bre-5 in an animal otherwise lacking bre-5 is sufficient for Cry
protein intoxication and providing a complementary result to
our mosaic experiments (6).
We similarly found that intestinal-specific expression of
wild-type bre-2 in a bre-2(ye31) mutant background and intes-
tinal-specific expression of wild-type bre-4 in a bre-4(ye13) mu-
tant background fully restored Cry toxin susceptibility to each
(Fig. 2, E and F). Thus, like bre-5, both glycosyltransferase
genes act in the intestine in their mediation of Cry protein
intoxication. The fact that the bre-2 gene complements a bre-2
mutant and that the bre-4 gene complements a bre-4 mutant
also confirms the identities of these genes. To demonstrate
specificity of rescue, we transformed a bre-5(ye17) mutant with
the wild-type cpr-1::bre-2 construct that fully rescues a bre-2
mutant. No rescue of the bre-5 mutant by the bre-2 gene was
seen (Fig. 2G) despite the fact that both are members of the
extended 1,3-glycosyltransferase family.
Toxin Uptake in C. elegans Is Associated with Active Toxin
and Requires bre-2, bre-4, and bre-3—We previously demon-
strated that bre-5 is required for Cry5B toxin to interact with
intestinal cells since bre-5(ye17) mutant animals fail to endo-
cytose Cry5B protoxin labeled with rhodamine (6). However,
because Cry proteins are produced as large (protoxin) precur-
sors that are proteolytically activated, it was not demonstrated
that toxin molecule taken up was the active toxin fragment or
that the toxin had to be functional to be taken up. To extend
these results, we fed C. elegans rhodamine-labeled Cry5B that
was full-length (protoxin), proteolytically activated with tryp-
sin (Fig. 3A), or boiled to inactive it. As reported (6), full-length
protoxin is readily taken up by intestinal cells into autofluo-
rescent gut granules, which are reported to be the secondary
lysosome (Fig. 3, B and C). We found that trypsin-activated
toxin is also endocytosed by intestinal cells (Fig. 3D). In con-
trast, inactivated toxin is not taken up (Fig. 3E). Thus, toxin
uptake into intestinal cells is associated with activated, func-
tional toxin.
In contrast to wild-type animals, bre-2(ye31) bre-4(ye13), and
bre-3(ye28) (bre-3 is discussed further below), mutant animals
do not endocytose either functional protoxin or trypsin-acti-
vated toxin into their intestinal cells (Fig. 3, F–K). Rhodamine
toxin seen in the intestinal lumen is not stably associated with
the intestinal membrane since bre-4(ye13) and bre-5(ye15) mu-
tant animals fed a pulse of rhodamine toxin flush the labeled
toxin from their lumen within 5–10 min; no residual binding
was detected (Fig. 3L, shown for bre-4(ye13)). These results
suggest that the glycosyltransferase genes make a component
required for toxin to interact with the plasma membrane of the
intestine. An alternative explanation, that these mutants are
all defective in general endocytosis by the intestine is unlikely
since all the mutants grow at relatively normal rates and have
good brood production and because we have already demon-
strated that bre-5(ye17) mutants are not obviously defective in
endocytosis (6).
bre-3 Encodes the C. elegans Homologue of Drosophila Egg-
head (egh)—Although the identities of bre-2 and bre-4 were not
obviously linked to each other or bre-5 apart from the fact all
are glycosyltransferase genes, the identification of bre-3 is
striking given the identity of bre-5. bre-3 was cloned by genetic
mapping followed by rescue with cosmid B0464 and then rescue
with the single ORF B0464.4. bre-3 encodes a putative glyco-
syltransferase belonging to family 2  transferases (Fig. 4A)
and includes aspartate residues conserved in this family. Many
enzymes in this family, including BRE-3, also contain a char-
acteristic QRXRW motif that is important for transferase func-
tion (16). Based on sequencing mutant alleles, Cry5B resist-
ance is the null phenotype for bre-3 since several known alleles
FIG. 2. Intestine-specific expression of bre-5, bre-2, and bre-4 are sufficient for Cry5B intoxication and confirm cloning of bre-2 and
bre-4. A and B, differential interference contrast (DIC) and fluorescence microscopy verifies intestine-specific expression of the cpr-1 promoter
driving BRE-5::HA (BRE-5::HA is in red, and 4,6-diamidino-2-phenylindole is in blue). Asterisks denote pharyngeal terminal bulb. C–G, images
of animals after 72 h of growth on Cry5B, all at the same magnification and oriented with heads pointing upper left. C–F are toxin-sensitive; G is
toxin-resistant. C, N2 on Cry5B. D, bre-5(ye17) transformed with cpr-1::bre-5 on Cry5B. E, bre-2(ye31) transformed with cpr-1::bre-2 on Cry5B. F,
bre-4 (ye13) transformed with cpr-1::bre-4 on Cry5B. G, bre-5(ye17) transformed with cpr-1::bre-2 on Cry5B; bre-2 fails to rescue the bre-5 mutant.
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(ye9 premature stop; ye28 internal deletion) are predicted to
eliminate protein function. RNA-mediated interference of bre-3
recreated Cry5B resistance, confirming this conclusion. bre-3
mutant animals appear otherwise healthy.
BRE-3 has a very high level of sequence identity to Drosoph-
ila EGGHEAD (EGH) (60% amino acid identity over their
entire lengths, Fig. 4A). BRE-3 also is highly similar to a
predicted EGH-like enzyme in A. gambiae (59% identity; Fig.
4A). BRE-3 and EGH differ in length by only two amino acids
at the very carboxyl terminus, and both are unique in their
respective genomes.
EGH is known to specifically catalyze the transfer of man-
nose to glucose with a 1,4-glycosidic linkage (17). BRE-3 and
EGH also display low, but detectable, levels of sequence iden-
tity to processive glycosyltransferases from bacteria (e.g. NodC
(Fig. 4A) and cellulose synthase, not shown), suggesting that
perhaps the invertebrate family evolved from the bacterial
family. Consistent with this hypothesis, analysis of potential
transmembrane regions for BRE-3, EGH, NodC, and other
proteins of this class indicate striking conservation of structure
not evident in sequence alignments. These enzymes are pre-
dicted to be anchored in the membrane at both the amino and
carboxyl termini, with the enzymatic domain (amino acids 80–
330 for BRE-3) all predicted to sit in the cytosol (Fig. 4, B–D).
BRE-3/EGH has no detectable amino acid sequence similarity
to proteins from vertebrates.
We expressed 2 HA-tagged BRE-3 under the control of the
cpr-1 intestinal promoter and analyzed its localization in intes-
tinal cells (Fig. 5A). BRE-3::HA protein localizes to a punctate
intracellular compartment. No detectable protein was seen at
the plasma membrane. These results are consistent with
BRE-3 acting as a glycosyltransferase that intracellularly mod-
ifies a Cry toxin receptor and not, despite the presence of
multiple putative TM domains, as a direct receptor for Cry
toxin at the plasma membrane. As with bre-2, bre-4, and bre-5,
intestinal-specific expression of bre-3 was sufficient to restore
susceptibility to toxin in a bre-3(ye28) mutant background (Fig.
5, B and C).
The Four bre Glycosyltransferase Genes Function in a Single
Pathway—The identity of the bre-3 gene as the C. elegans
putative egh homologue is striking given the previous identifi-
cation of bre-5 as having some sequence identity to Drosophila
brainiac (brn). brn and egh display similar neurogenic pheno-
types in Drosophila, act in the same genetic pathway in epi-
thelial morphogenesis of Drosophila follicle cells, and have
been shown to catalyze consecutive glycosylation reactions (14,
17–20). Based on enzymology, it is predicted that egh and brn
function to synthesize Drosophila glycosphingolipids, although
FIG. 3. Uptake of Cry5B toxin into intestinal cells is associated with active toxin and is defective in bre-2, bre-4, and bre-3 mutants.
A, protoxin and trypsinized toxin visualized by SDS-PAGE. Lane 1, molecular weight markers; lane 2, purified Cry5B protoxin; lane 3, purified
Cry5B toxin processed with trypsin. C–L, fluorescent images of animals fed rhodamine-labeled toxins. B and C, matching differential interference
contrast and fluorescent image of wild-type animal fed labeled protoxin. C, wild-type intestines take up labeled protoxin. D, wild-type intestines
take up trypsinized toxin. E, wild-type intestines do not take up inactivated protoxin. F–H, bre-2(ye31), bre-4(ye13), and bre-3(ye28) mutant animals
fail to take up active, labeled protoxin. I–K, bre-2(ye31), bre-4(ye13), and bre-3(ye28) mutant animals fail to take up active, labeled trypsinized toxin.
L, progressive and rapid loss of rhodamine signal in a bre-4(ye13) animal fed labeled toxin in a well and then transferred to an E. coli lawn
(wash-out experiment). Asterisks denote pharyngeal terminal bulb; arrows denote intracellular intestinal granules; arrowheads indicate intestinal
lumen. B-K are at the same magnification.
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glycosphingolipid defects in the Drosophila mutants have yet to
be shown. The similarities of bre-3 to egh and bre-5 to brn
suggest that Cry protein intoxication in C. elegans uses the
same pathway as that required for epithelial morphogenesis in
Drosophila. To test whether bre-3 and bre-5 act in a common
pathway for Cry5B intoxication, we examined the dose re-
sponse of animals homozygous for the molecular null alleles
bre-3(ye28), bre-5(ye17), and the double mutant bre-3(ye28),bre-
5(ye17) to the Cry5B-related crystal toxin Cry14A (see “Exper-
imental Procedures”). Each single and the double mutant
shows a similar level of Cry toxin resistance (Fig. 6). These data
indicate that, like egh and brn, bre-3 and bre-5 function in a
single, common genetic pathway.
Given their similar phenotypes and identification as glyco-
syltransferase genes, we hypothesized that bre-2 and bre-4 also
function in the same pathway as bre-3-bre-5. To test this hy-
pothesis double mutants were made between bre-4(ye13) and
each of the other mutants. The lesions in the alleles used are
predicted to result in deletions of required catalytic residues,
except bre-2(ye31), which results in a single amino acid change
at a highly conserved residue. Resistance to Cry14A toxin was
extensively quantitated in all single and double mutants at
three doses (Fig. 7). Resistance levels of each of the four single
mutants are similar, and at any given dose, resistance levels of
all double mutant strains were not statistically different (p 
0.2) in pairwise comparisons with the reference bre-4(ye13)
single mutant strain. Thus bre-2, bre-3, bre-4, and bre-5 form
an extended single genetic pathway for Cry toxin resistance.
bre-5 Is the Functional Homologue of Drosophila brn and
Provides the Major UDP-GlcNAc:Man N-Acetylglucosaminyl-
transferase Activity in C. elegans—Although BRE-3 and EGH
share high levels of amino acid identity and are unique in their
respective genomes, BRE-5 and BRN are 29% identical (37%
in their predicted catalytic domains) and overall belong to the
larger family of 1,3 glycosyltransferases, of which there are
many predicted in both the C. elegans and Drosophila genomes
FIG. 4. bre-3 encodes the C. elegans EGGHEAD homologue. A, the protein sequence shown is assembled by translating bre-3 cDNA.
Alignments to EGGHEAD from D. melanogaster, the EGGHEAD homologue in A. gambiae, and the NodC protein from Rhizobium leguminosarum
are shown. Identical residues between BRE-3, EGH, and A. gambiae EGH are highlighted in black boxes. Double underlines indicate conserved
motifs known to play key catalytic roles in related glycosyltransferases. Mutations observed in various bre-3 alleles are also shown. The bre-3(ye28)
allele is due to a DNA deletion corresponding to residues beneath the solid line and leads to a frameshift over the remainder of the coding region.
B–D, predicted transmembrane regions and topology of BRE-3, EGH, and NodC, respectively.
FIG. 5. BRE-3 is in cytoplasmic puncta and is required in the intestine for intoxication by Cry5B. A, double staining (HA is in red;
4,6-diamidino-2-phenylindole (DAPI) is in blue) of HA-tagged BRE-3 driven by the cpr-1 promoter. BRE-3 localizes to cytoplasmic puncta and is
not seen at the plasma membrane. B, a resistant bre-3(ye28) animal on Cry5B toxin. C, bre-3(ye28) transformed with cpr-1::bre-3::HA construct
demonstrating intestinal-specific rescue.
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(including bre-2; see above). To therefore test whether BRE-5
and BRN are true homologues, we drove expression of a wild-
type copy of C. elegans bre-5 cDNA in Drosophila mutant for
brn. Using three different promoters, we found that both brn
and bre-5 could complement the lethality associated with Dro-
sophila homozygous for the brn1.6P6 (21) mutation (Table I). In
contrast, a human 1,3-N-acetylglucosaminyltransferase was
not able to rescue brn lethality. Thus, BRE-5 is the C. elegans
homologue of Drosophila BRN.
The functional homology of bre-5 and brn predicts that
bre-5 should encode N-acetylglucosaminyltransferase (Glc-
NAc-transferase) activity. Enzymatic experiments performed
with extracts from wild-type animals demonstrate that C. el-
egans has GlcNAc-transferase activity when Man1,4Glc-
pNP is used as the acceptor (the preferred acceptor for BRN)
(Fig. 8). This activity returns almost to background levels
when extracts are prepared from bre-5(ye17) homozygous
animals instead of wild type (Fig. 8). These data indicate that
BRE-5 is a UDP-GlcNAc:Man N-acetylglucosaminyltrans-
ferase and that BRE-5 provides the majority of such activity
in C. elegans.
TABLE I
Complementation of D. melanogaster brn1.6P6 by bre-5
UAS transgenic Line
GAL4 transgenic lines
Actin GAL4 Armadillo GAL4 Heat shock GAL4
% rescuea
brn 87 (47) 97 (403) 85 (124)
bre-5 (line 1) 25 (231) 20 (289) 25 (146)
bre-5 (line 2) 78 (117) 57 (266) 35 (166)
Human 3GnT-IV 0 (90) 0 (116) 0 (130)
a Rescue is given as percentage of hatched forked, brn1.6P6 males
relative to the number of hatched males carrying the balancer chromo-
some FM6,w1. The number of males used for the calculation is indicated
in parentheses.
FIG. 6. bre-3 and bre-5 function in a
single genetic pathway. Cry14A dose-
response curves for N2, bre-3(ye28), bre-
5(ye17), and bre-3(ye28),bre-5(ye17) ani-
mals. The strains (as shown) were
exposed to four doses of Cry14A. Data
shown represent the average sizes at-
tained over the experiment as a fraction
of controls fed non-toxic E. coli. Each data
point represents the average size of 8–20
animals (on average 12).
FIG. 7. All four bre genes function in a common genetic pathway. The strains (as shown) were exposed to 37 ng/ml (black bars), 67 ng/ml
(gray bars), and 134 ng/ml (white bars) of Cry14A. Data shown represent the average sizes attained over the experiment as a fraction of controls
fed non-toxic E. coli. Error bars represent the S.D. from the mean of averages over three independent experiments, each employing 20–30 animals
per condition.
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DISCUSSION
Characterization of the four major genes that mutate to
confer resistance to pore-forming crystal toxin in C. elegans,
bre-2, bre-3, bre-4, and bre-5, has led to the identification of a
single glycosylation pathway. Components of this same path-
way are active in insects. The egh and brn glycosyltransferase
genes required for epithelial development in Drosophila corre-
spond to the bre-3 and bre-5 Cry5B resistance genes in C. el-
egans. We demonstrate that bre-5 and brn are functional ho-
mologues. It is likely that bre-3/egh are functional homologues
as well since bre-3 and egh are unique in their respective
genomes, share a high level of amino acid identity, and function
in a common pathway with bre-5/brn.
Given the lack of a vertebrate bre-3/egh homologue, the func-
tional conservation of bre-5 and brn, and the fact that bre-5 and
brn are more similar to each other than they are to mammalian
1,3-glycosyltransferases, it appears that the bre-3/egh-bre-5/
brn pathway is an invertebrate-specific glycosylation pathway.
Enzymatically, egh and brn catalyze consecutive steps that are
consistent with the production of glycosphingolipids, although
this has yet to be demonstrated in vivo. Our identification of
two additional genes, bre-2 and bre-4, extends this pathway.
The bre-4 gene product has been previously demonstrated to
have glycosyltransferase activity (8); the bre-2 gene product
has not, and thus, BRE-2 should be regarded as a putative
glycosyltransferase. A likely bre-4 homologue in Drosophila is
noted above.
All four bre mutants are defective in the uptake of toxin into
intestinal cells. Furthermore, chase experiments in live ani-
mals indicate that toxin is not significantly associated with
intestinal membranes in bre-4 or bre-5 mutant animals. These
data suggest that the bre genes are involved in promoting the
interaction of Cry5B and Cry14A crystal toxins with the intes-
tinal plasma membrane. The simplest interpretation of these
data is that the bre genes synthesize an oligosaccharide that is
transported to the apical membrane of the intestine that serves
as a receptor for crystal toxins (Fig. 9). Ample precedent exists
for bacterial toxins binding to extracellular carbohydrates in-
cluding aerolysin, cholera toxin, and Shiga toxin. Because loss
of any of the bre enzymes leads to high levels of resistance to
Cry5B, we hypothesize that this receptor is the major receptor
for Cry5B. In the case of Cry14A, the reduced level of resistance
conferred by the mutants suggests that other receptors can
partly compensate in the absence of the bre oligosaccharide
(Fig. 9). An alternative interpretation of our data is that the bre
genes do not make a direct receptor for toxin but, rather,
influence the membrane or membrane proteins in a way that
promotes toxin binding and/or uptake.
This work reiterates and provides striking in vivo genetic
evidence for the importance of carbohydrates in the interaction
of bacterial toxins with their host. Our screen for healthy,
robust resistant mutants did not uncover any mechanisms of
resistance other than the bre glycosylation pathway. Given the
number of alleles we isolated for each of these genes, it is likely
that the list of strong, healthy Cry5B resistance genes is com-
plete or nearly complete. Our data also suggest that receptor
binding of a bacterial pore-forming toxin is a central target for
potential therapeutics. For example, the modulation of carbo-
hydrates (e.g. using synthetic carbohydrates as competitive
inhibitors) could have therapeutic benefits against bacterial
toxins that require carbohydrates for interacting with the host.
Such a strategy is being explored with Shiga toxin in mammals
(22).
Our results have important implications for the biology of
Cry toxins and Cry toxin resistance as well. The identification
of bre-2, bre-3, and bre-4 doubles the number of Cry toxin
resistance genes known. That the bre genes mutate to resist-
ance for two divergent crystal proteins, Cry5B and Cry14A
(34% identical at the amino acid level) suggests that they will
be relevant to the biology of other Cry toxins as well. Signifi-
cantly, Cry14A has been reported to be toxic to coleopteran
insects (23), suggesting that insects could use the same recep-
tor. In addition, some insect resistance to Cry toxin has been
has been correlated with changes in complex carbohydrate
structures (24, 25). Along with the striking conservation of the
bre-3-bre-5 pathway with the egh-brn pathway in insects, these
observations suggest our results may be relevant to Cry toxin
resistance in insects as well. Unlike the C. elegans bre mutants,
Drosophila mutants in this pathway are often lethal. Thus
insects may be less able to tolerate loss of function of this
pathway. Perhaps this is part of the reason for the high efficacy
of insecticidal Cry toxins even over long periods of selection
(26). However, viable/sterile mutant alleles of egh and brn
exist. It is, therefore, possible that mutations in these could
contribute to the development of resistance in insects. This
contribution could be investigated by analysis of homologous
sequences in resistant insects and could provide vital informa-
tion about how invertebrate pests and disease vectors evolve
resistance to Cry toxins and how the emergence of resistance
can be minimized.
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FIG. 8. bre-5 encodes for the majority of UDP-GlcNAc:Man N-
acetylglucosaminyltransferase activity in C. elegans. Crude ex-
tracts were tested for the ability to transfer radiolabeled GlcNAc from
UDP-[6-3H]GlcNAc to the acceptor sugar Man1,4Glc-pNP.
FIG. 9. An oligosaccharide receptor-based model for the bre
genes in intestinal cells that includes the overlapping, but non-
identical requirements of the bre genes for Cry5B and Cry14A
intoxication.
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Characterization of mucin-type core-1 b1-3
galactosyltransferase homologous enzymes in Drosophila
melanogaster
Reto Mu¨ller1, Andreas J Hu¨lsmeier1, Friedrich Altmann2, Kelly Ten Hagen3, Michael Tiemeyer4
and Thierry Hennet1
1 Institute of Physiology, University of Zu¨rich, Switzerland
2 Institute of Chemistry, Universita¨t fu¨r Bodenkultur, Wien, Austria
3 Developmental Glycobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda,
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Mucin-type O-glycosylation is initiated by the transfer
of N-acetylgalactosamine (GalNAc) to the hydroxyl
group of selected serine and threonine residues. This
transfer is catalyzed by a family of polypeptide N-ace-
tylgalactosaminyltransferase (ppGalNAcT) enzymes
localized in the Golgi apparatus [1]. The resulting
GalNAc(a1-O)Ser ⁄Thr epitope, also known as the
Tn-antigen [2], is elongated in most cells by the addi-
tion of galactose (Gal) via a b1-3 linkage, thus forming
the core-1 Gal(b1-3)GalNAc(a1-O) structure. Whereas
more than 15 ppGalNAcTs have been identiﬁed in
mammalian genomes, only a single core-1 b1-3 galacto-
syltransferase (b3GalT) enzyme has been described to
date [3,4]. The importance of the early core-1 b3GalT
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Mucin type O-glycosylation is a widespread modiﬁcation of eukaryotic pro-
teins. The transfer of N-acetylgalactosamine to selected serine or threonine
residues is catalyzed by a family of polypeptide N-acetylgalactosaminyl-
transferases localized in the Golgi apparatus. The most abundant elonga-
tion of O-glycans is the addition of a b1-3 linked galactose by the core-1
b1-3 galactosyltransferase (core-1 b3GalT), thereby building the T-antigen
or core-1 structure Gal(b1-3)GalNAc(a1-O). We have isolated four
Drosophila melanogaster cDNAs encoding proteins structurally similar to
the human core-1 b3GalT enzyme and expressed them as FLAG-tagged
proteins in Sf9 insect cells. The identity of these D. melanogaster b3GalT
enzymes with a core-1 b3GalT activity was conﬁrmed by utilization of
MUC5AC mucin derived O-glycopeptide acceptors. In addition to the
core-1 b3GalT activity toward O-glycoprotein substrates, one member of
this enzyme family showed a strong activity towards glycolipid acceptors,
thereby building the core-1 terminated Nz6 glycosphingolipid. Transcripts
of the embryonically expressed core-1 b3GalTs were found in the mater-
nally deposited mRNA, in salivary glands and in the amnioserosa. The
presence of multiple core-1 b3GalT genes in D. melanogaster suggests an
increased complexity of core-1 O-glycan expression, which is possibly rela-
ted to multiple developmental and physiological functions attributable to
this class of glycans.
Abbreviations
2AB, 2-aminobenzamide; DIG, digoxigenin; b3GalT, b1-3 galactosyltransferase; Gal, galactose; GalNAc, N-acetylgalactosamine; GU, glucose
unit; ppGalNAcT, polypeptide N-acetylgalactosaminyltransferase; TBS, Tris-buffered saline.
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activity was demonstrated by the embryonic lethality
observed in mice bearing an inactivated core-1 b3GalT
gene [5]. These core-1 b3GalT1-null mice exhibited an-
giogenesis defects and hemorrhages possibly caused by
defective interactions between endothelial cells and the
extracellular matrix, highlighting the signiﬁcance of
core-1 mucin structures in mammalian development.
Nine ppGalNAcT genes have been described in
D. melanogaster [6] but no core-1 b3GalT gene has
been characterized up to now. As shown by peanut
agglutinin binding, the distribution of core-1 glycans is
regulated in a tissue- and stage-speciﬁc manner during
embryonic development in D. melanogaster [7,8]. Core-
1 glycans are found on mucin glycoproteins isolated
from different D. melanogaster cell lines and tissues
[9–11]. In addition, core-1 glycans occur on short anti-
bacterial peptides such as Drosocin in Drosophila [12]
and Diptericin in Phormia [13]. Remarkably, the
O-glycan moiety of these peptides increases their anti-
bacterial activity.
Protein sequence domains of glycosyltransferases are
typically conserved between animal species, thus facili-
tating the identiﬁcation of orthologous proteins across
genomes. However, structural similarity alone is insuf-
ﬁcient to conclusively assign an enzymatic activity to a
novel protein as structurally related proteins may actu-
ally utilize different acceptor and donor substrates. To
better understand the molecular pathways of O-glyco-
sylation in insects, we have isolated the four closest
homologous cDNAs to the human core-1 b3GalT in
D. melanogaster and characterized their respective
enzymatic activity and their expression pattern during
early development.
Results
A search for D. melanogaster genes encoding proteins
similar to the mammalian core-1 b3GalT enzymes
yielded several hits as noted previously [3]. Using the
tblastn algorithm [14] on the D. melanogaster genome
sequence available through the BDGP server (http://
www.fruitﬂy.org), we retrieved the cDNAs encoding
the four closest homologous proteins to the human
core-1 b3GalT enzyme (Fig. 1). The overall sequence
identity ranged from 31% to 43%, whereas several
regions were highly conserved between the retrieved
proteins and the human core-1 b3GalT. The detection
of conserved TWG, DDD and EDV motifs, which are
typical of b1,3 glycosyltransferase proteins [15], sup-
ported the potential functional orthology with the
core-1 b3GalT enzyme (Fig. 1). The amino acid
sequences retrieved from the D. melanogaster genome
Fig. 1. Alignment of core-1 b3GalT candidate proteins. CLUSTALW [34] alignment of the human core-1 b3GalT protein (hC1b3GalT, accession:
NP_064541) and of four similar D. melanogaster proteins. Amino acids conserved in all proteins are shaded in black. The TWG-, DXD- and
EDV-motifs are boxed. Percentages of sequence identity of the D. melanogaster proteins to the human core-1 b3GalT are indicated in the
final column.
Core-1 b1-3 galactosyltransferases in Drosophila R. Mu¨ller et al.
4296 FEBS Journal 272 (2005) 4295–4305 ª 2005 FEBS
were in agreement with the gene models proposed by
Flybase, with the exception of CG13904-1. The candi-
date protein of Flybase, i.e., CG13904, was modeled
as a fusion protein by the gene prediction algorithm,
where it represents a large protein of 680 amino acids
with two similar domains. However, a comparison of
this model with canonical b1-3 glycosyltransferases
suggested that CG13904 represented two distinct genes
arranged in tandem. However, we were unable to iso-
late a cDNA with an ORF consistent with a full length
protein encoded by the 3¢ located gene of the CG13904
locus either from adult, embryonic, or Schneider-2 cell
cDNA. The cDNAs representing CG9520, CG8708
and CG13904-1 were isolated from embryonic mRNA
whereas the cDNA for CG2975 could not be found in
embryonic, but only in larval and adult mRNA.
The retrieved candidate cDNAs were expressed as
N-terminally FLAG-tagged recombinant proteins in
Sf9 cells. The expression of full-length recombinant
proteins in Sf9 cells was conﬁrmed by western blot
analysis based on the detection of the FLAG-epitope
(data not shown). The presence of this FLAG-epitope
also enabled the capture and partial puriﬁcation of the
recombinant proteins for further characterization. To
assay the enzymatic activity of each candidate protein,
we ﬁrst tested the transfer of Gal to GalNAc(a1-O)Bz
using equal amounts of FLAG-recombinant proteins.
CG9520 exhibited a high activity, whereas CG13904-1,
CG2975 and CG8708 were only moderately active
(Table 1). The screening for possible additional glyco-
syltransferase activity was extended by assaying the
donor substrates UDP-Gal, UDP-GalNAc, UDP-Glc-
NAc, UDP-GlcA and UDP-Glc against the acceptor
monosaccharides Gal, GalNAc, GlcNAc, Glc, fucose,
mannose and xylose, each derivatized to pNP in either
a and b anomeric conﬁguration. We also tested var-
ious assay conditions with different detergents and
detergent concentrations, by using other divalent cati-
ons, by applying a range of pH and temperature. The
four enzymes showed similar requirement for Mn2+
and were most active at 25 C, pH 6.6 and in the pres-
ence of 0.4% (v ⁄ v) Triton X-100. The enzymes were
more active toward a-anomeric over b-anomeric
monosaccharides with a marked preference for Gal-
NAc(a1-O)Bz. CG9520 showed also a pronounced ga-
lactosyltransferase activity toward GlcNAc(a1-O)pNP,
Gal(a1-O)pNP, GalNAc(b1-O)pNP and Man(a1-
O)pNP (Table 1).
To verify that the active D. melanogaster core-1
b3GalT homologs indeed yielded a b1-3 linkage, we
produced 10 nm of galactosylated GalNAc(a1-O)Bz
using each of the four active galactosyltransferases
CG9520, CG8708, CG13904-1 and CG2975 and ana-
lyzed their respective product by HPLC and MS. The
disaccharides generated were ﬁrst isolated by normal-
phase chromatography. The product peaks were identi-
ﬁed by electrospray-MS by their mass of 496.16 Da
([M + Na+] ion). The linkage of the GalNAc residue
in the disaccharide was investigated by permethylation
analysis. In the gas-chromatographic separation of
partially methylated alditol acetates, the GalNAc
derivative eluted slightly after the derivative from a
4-substituted GlcNAc (reference made from bovine
fetuin; 15.1 vs. 14.3 min). Partially methylated alditol
acetates yield characteristic fragmentation patterns
dependant on the substitution positions of a residue
[16]. The GalNAc derivative gave fragment ions which
strongly indicated a 3-substitution of the acceptor Gal-
NAc whereas ions pointing at a 4- or 6-substitution
were missing (Fig. 2).
Considering the artiﬁcial nature of the GalNAc(a1-
O)Bz substrate, we also measured the core-1 b3GalT
activity of the four active D. melanogaster enzymes
towards various GalNAc(a1-O)glycopeptide, glycopro-
tein and glycolipid acceptors. The GalNAc(a1-O)glyco-
peptides assayed were derived from the MUC5AC
sequence GTTPSPVPTTSTTSAP, where either Thr at
position 3 (MUC5AC-3), Thr at position 13
(MUC5AC-13) or both Thr3 and Thr13 residues
(MUC5AC-3 ⁄ 13) carried a GalNAc(a1-O) monosac-
charide. These glycopeptides have been shown to act
as substrates for mammalian and D. melanogaster
ppGalNAcT enzymes [6]. Whereas CG9520 was able
to transfer Gal to the three glycopeptides at equal efﬁ-
ciency, CG8708 showed a preference for the diglycosyl-
ated peptide MUC5AC-3 ⁄ 13 and CG13904-1 was
more active toward MUC5AC-13 and MUC5AC-3 ⁄13
Table 1. Monosaccharide acceptor specificity of D. melanogaster
core-1 b3GalT homologs.
Acceptor (10 mM)
Enzymea (pmol GalÆmin)1ÆmL)1)
BRNb CG9520 CG8708 CG13904-1 CG2975
GalNAc(a1-O)Bz 36 27 415 107 170 182
GalNAc(b1-O)pNP 30 1126 30 39 37
GlcNAc(a1-O)pNP 24 14 426 55 120 32
GlcNAc(b1-O)pNP 25 76 21 35 27
Gal(a1-O)pNP 27 2411 32 43 30
Gal(b1-O)pNP 38 44 30 37 34
Glc(a1-O)pNP 22 62 28 31 28
Man(a1-O)pNP 29 205 22 59 29
Fuc(a1-O)pNP 31 58 23 40 31
Xyl(a1-O)pNP 35 64 24 37 31
a Anti-FLAG-beads bound lysate of Sf9 cells. b The D. melanogaster
b1-3 N-acetylglucosaminyltransferase brainiac (BRN) was used as
negative control.
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(Table 2). CG2975 was inactive towards the three
MUC5AC glycopeptides, although control reactions
using GalNAc(a1-O)Bz conﬁrmed the inherent galacto-
syltransferase activity of this protein. By comparison,
when typical core-1 containing mucin glycoproteins
were used as acceptors, only CG9520 showed a signiﬁ-
cant galactosyltransferase activity against asialo-ovine
and asialo-bovine submaxillary mucins (Table 2).
Drosophila melanogaster glycolipids have been shown
to contain the Gal(b1-3)GalNAc terminal epitope, as
for example found in the Nz6 glycolipid Gal(b1-3)Gal-
NAc(a1-4)GalNAc(b1-4)[phosphoethanolamine-6]Glc-
NAc(b1-3)Man(b1-4)Glc(b1-O)Cer [17,18]. To analyze
whether D. melanogaster core-1 b3GalT homologs
could catalyze the elongation of glycolipid substrates,
we tested total glycolipids isolated from the D. melano-
gaster Schneider-2 cells and from Spodoptera frugiperda
Sf9 cells as possible acceptors. Only CG9520 was able
to transfer Gal to glycolipid acceptors, and this only to
Schneider-2 derived glycolipids (Table 2). Considering
this signiﬁcant activity of CG9520 towards Schneider-2
glycolipids, we have analyzed the products of this reac-
tion by TLC and HPLC. The TLC proﬁle of in vitro
[14C]Gal-labeled Schneider-2 glycolipids showed several
products, termed A–E in Fig. 3, which were isolated
from the TLC and subjected to ceramide glycanase
digestion. The released glycans were derivatized with
2-aminobenzamide (2AB) prior to GlycoSep–N normal
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Fig. 2. Linkage analysis of the disaccharide
Gal-GalNAc. The fragment spectrum of the
partially methylated alditol acetate derived
from the GalNAc residue is shown together
with a fragmentation scheme. Diagnostic
fragments are shown in bold. Equally
important is the absence of fragments point-
ing at a 4- (e.g. 233 and 203) or 6-linkage
(e.g. 189 and 203).
Table 2. Specificity of D. melanogaster core-1 b3GalT homologs toward complex type acceptors.
Acceptor type Name
Enzymea
BRNb CG9520 CG8708 CG13904-1 CG2975
Glycopeptide
(pmol GalÆmin)1ÆmL)1)
MUC5AC-3c 2 10 225 19 97 0
MUC5AC-13c 0 12 398 184 184 0
MUC5AC-3 ⁄ 13c 0 12 718 442 201 0
Glycoprotein
(pmol GalÆmin)1ÆmL)1)
asOSMd 8 266 17 8 8
asBSMe 3 223 4 3 5
Glycolipid (d.p.m.Æh)1) Sf9f 19 80 8 12 12
Schneider-2f 12 1128 15 12 9
a Anti-FLAG-beads bound lysate of Sf9 cells. b The D. melanogaster b1-3 N-acetylglucosaminyltransferase brainiac (BRN) was used as negative
control. c O-glycopeptide MUC5AC acceptors assayed at 2.5 mM ( 4.5 lgÆlL)1). Amino acids with GalNAc are in parentheses. MUC5AC-3,
GT[T]PSPVPTTSTTSAP; MUC5AC-13, GTTPSPVPTTST[T]SAP; MUC5AC-3 ⁄ 13, GT[T]PSPVPTTST[T]SAP. d asOSM, asialo-ovine submaxillary
mucin, assayed at 1.5 lgÆlL)1. e asBSM, asialo-bovine submaxillary mucin, assayed at 0.35 lgÆlL)1. f Assayed at 0.1 lg mannose equiva-
lentsÆlL)1.
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phase chromatography, calibrated with 2AB-labeled
dextran oligomers to allow the expression of the retent-
ion times as glucose units (GU) (Fig. 4). Of the TLC
bands analysed, the glycan released from band B co-
eluted with authentic Nz6 saccharide [17] at 6.09 GU.
The ceramide glycanase products released from bands
A, C and D differed in their elution position of about
one GU from the Nz6 saccharide (Fig. 4). The similar
HPLC proﬁles obtained for C and D likely accounts
for the loss of acid labile groups after mild acid hydro-
lysis treatment. The 2AB-glycan isolated from band E
coeluted with authentic octaosylceramide Nz8 sacchar-
ide at 7.94 GU, suggesting that E could represent Gal-
extended Nz7. This result underlined the function of
CG9520 as a possible Nz6-synthesizing enzyme.
The patterns of core-1 b3GalT gene expression were
investigated during early ﬂy development by in situ
labeling in whole mount embryos with digoxigenin
(DIG)-labeled probes. CG9520 mRNA was deposited
into the embryo by the mother, was lost quickly there-
after and reappeared at around stage 9–10 to be
expressed in a wide stripe in the amnioserosa of the
embryo (Fig. 5), which is required for dorsal closure
during ﬂy development [19]. Finally, the staining fol-
lowed the vanishing amnioserosa. By contrast, the two
late embryonically expressed CG8708 and CG13904-1
genes were both expressed solely in salivary glands
(Fig. 6).
Discussion
In the present study, we have shown that several
D. melanogaster b3GalT enzymes can produce the
mucin-type core-1 structure when assayed in vitro. The
O-glycan core-1 biosynthetic activity could be estab-
lished for three of these enzymes, as shown by the suc-
cessful galactosylation of MUC5AC mucin derived
glycopeptides. The comparison between the activity
of D. melanogaster core-1 b3GalT enzymes towards
MUC5AC glycopeptides showed a substrate preference
associated with the glycopeptide structure itself because
CG8708 preferred the diglycopeptide MUC5AC-3 ⁄ 13.
The fact that these two core-1 b3GalT enzymes hardly
glycosylated typical O-glycoproteins such as the asialo-
ovine and asialo-bovine submaxillary mucins also
speaks for a recognition of the peptide sequence itself
by core-1 b3GalT proteins. In addition to O-glycopep-
tide acceptors, the CG9520 enzyme described here was
able to transfer Gal to neutral glycolipids isolated from
D. melanogaster Schneider-2 cells. The multiple reac-
tion products identiﬁed after TLC and HPLC analysis
showed that CG9520, considering its loose acceptor
speciﬁcity (Table 1), probably added Gal to glycolipids
of the Nz-series terminated with aGalNAc, bGalNAc
and bGlcNAc such as Nz5, Nz4 ⁄Nz8 and Nz7, respect-
ively [17]. The low core-1 b3GalT activity detected for
CG8708 and CG13904-1 in comparison to that of
CG9520 could indicate that they do not represent true
core-1 b3GalT enzymes. However, as mentioned above,
it is also possible to explain this difference if the
enzymes do recognize the peptide backbone in the con-
text of the acceptor substrate. Similarly, the characteri-
zation of the family of ppGalNAcT in several
organisms has shown that the glycosyltransferase activ-
ities measured in vitro can vary over several orders of
magnitude depending on the substates applied [6,20].
In mammalian cells, proper core-1 b3GalT activity
has been shown to rely on interactions with the
structurally related cosmc protein, which is devoid of
glycosyltransferase activity but acts as a chaperone
A
B
C
D
E
Nz3
nrB
nrB
0259GC
Gal GlcNAc Gal Gal GlcNAc Gal
nrB
nrB
0259GC
Fig. 3. Extension of glycolipids by CG9520. Glycolipids isolated from
Schneider-2 cells were incubated with CG9520 and with the b1-3
N-acetylglucosaminyltransferase brainiac (BRN) together with the
donor substrates indicated, i.e. UDP-[14C]Gal or UDP-[14C]GlcNAc.
Reaction products were separated by TLC and detected by orcinol
staining (left panel) and autoradiography for 24 h (right panel). The
position of the BRN glycolipid product Nz3 [17] is marked in the right
margin and the five products resulting from CG9520 extension are
marked from A to E.
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for the core-1 b3GalT enzyme [21]. Whereas no
homologous sequence to cosmc could be retrieved
from the D. melanogaster genome, we did identify, in
addition to the four core-1 b3GalT cDNAs charac-
terized here, ﬁve more genes showing a similarity to
core-1 b3GalT between 28 and 33% at the protein
Fig. 4. HPLC profiling of glycolipid-derived
oligosaccharides. The upper panel shows
the normal phase chromatography fluores-
cence profile of 2AB labeled dextran oligo-
mers corresponding to GU1-11. The elution
positions of 2AB labelled Nz6 and Nz8 sac-
charides derived from authentic D. melano-
gaster glycolipids [17] are indicated by
diamonds at 6.09 and 7.94 GU, respectively.
(A–E) show the elution profiles of [14C]Gal-
labeled, ceramide glycanase released and
2AB-derivatized glycolipid saccharides isola-
ted from the corresponding TLC bands A-E
(see Fig. 3).
Fig. 5. Embryonic localization of CG9520
transcripts. The expression pattern of the
CG9520 gene was detected by whole
mount in situ hybridization during early
D. melanogaster development. (A) Stage-2
embryo displaying the maternal deposition
of CG9520 mRNA in the embryo. (B) Stage-
11 embryo with staining in the amnioserosa.
(C) Lateral view of a stage-12 embryo; (D)
Dorsal view of stage-12 embryo.
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sequence level. The expression of these ﬁve genes in
Sf9 cells failed to reveal any glycosyltransferase
activity (data not shown), suggesting that some of
these inactive proteins may act like cosmc as chaper-
ones for core-1 b3GalT. However, the combined co-
expression of active and inactive D. melanogaster
core-1 b3GalT enzymes did not affect in any manner
the glycosyltransferase activity measured in Sf9 cells
(data not shown).
In the present study, we have reported the presence
of at least three core-1 b3GalT genes in the D. melano-
gaster genome. One reason for this higher number of
core-1 b3GalTs in D. melanogaster may be related
to differences in the regulation of gene expression
between insects and mammals. The transcriptome of
D. melanogaster is split into an adult and an embry-
onic one [22], potentially suggesting that the O-gly-
come of adult D. melanogaster may be constructed by
glycosyltransferases that are not expressed during
embryogenesis and early development. Alternatively, it
is possible that insect core-1 b3GalT enzymes fulﬁl
multiple tasks in various physiological processes.
Adaptation to pathogens and to environmental stress
often lead to lineage-speciﬁc expansion of gene clusters
involved in such responses [23]. In this context, the
speciﬁc expansion of core-1 b3GalT genes in D. mela-
nogaster may be interpreted in this way, as it has been
observed for the lineage-speciﬁc expansion of glycosyl-
transferase families in animal genomes [24].
The expression patterns of the three embryonically
expressed, active core-1 b3GalT genes during early
D. melanogaster development revealed the presence of
transcripts in salivary glands and in the transient struc-
ture called amnioserosa. The presence of at least
two ppGalNAcTs and two core-1 b3GalTs suggests
requirement of the T-antigen on proteins of the saliv-
ary glands. A potential target protein in embryonic
salivary glands represents the secreted mucin-type glue
protein encoded by the gene salivary gland secretion 4
[25,26]. Salivary gland secrete is rich in carbohydrates
and most salivary gland secreted proteins are suspected
to be glycosylated because of their behavior in poly-
acrylamide gradients [26]. Previous studies based on
lectin histochemistry with the Gal(b1-3)GalNAc-bind-
ing lectin peanut agglutinin failed to reveal any signal
in embryonic salivary glands [8], which could mean
that salivary O-glycan chains are elongated, thus abro-
gating peanut agglutinin binding. Furthermore, the
peanut agglutinin staining in the developing nervous
system documented by D’Amico and Jacobs [8] could
not be conﬁrmed in our in situ hybridization study.
The comprehensive testing of all core-1 b3GalT homo-
logous genes during Drosophila development will show
whether other genes are expressed in the tissues that
are positive for peanut agglutinin binding.
Transcripts of the CG9520 core-1 b3GalT gene were
ﬁrst detected as maternally deposited mRNA, in the
amnioserosa and also in salivary glands. The amnio-
serosa separates two epithelial layers, the lateral and
the dorsal epidermis until resorption of the yolk sac,
allowing the epithelial layers to meet at the dorsal mid-
line. The speciﬁc expression of CG9520 in the amnio-
serosa suggests a role for glycosylation in this process.
However, the strong activity of the CG9520 enzyme
towards glycolipid acceptors renders the interpretation
of this potential involvement challenging. A precise
structural analysis will be required to clarify whether
O-glycoproteins or glycolipids mediate critical inter-
Fig. 6. Salivary gland expression of CG8708
and CG13904-1. The expression of the two
core-1 b3GalT genes during embryogenesis
was confined to salivary glands. The four
panels show ventral views of stage-16
embryos.
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actions in the process of dorsal closure. In general, the
dual acceptor speciﬁcity of CG9520 together with the
identiﬁcation of multiple core-1 b3GalT enzymes in
D. melanogaster will make it difﬁcult to determine
whether mucin-type O-glycosylation is essential for the
development or survival of insects as it has been dem-
onstrated for mammals using core-1 b3GalT gene dis-
ruption in the mouse. However, the sophisticated
genetics of the fruit ﬂy as well as many available
mutants should enable us to discern which of the
members of this family are essential for development
as well as eventually decipher their in vivo substrates.
Experimental procedures
Cloning of Drosophila cDNAs
Total RNA was extracted from tight-rod disintegrated
0–24 h embryo and adult OregonR D. melanogaster using
Tri-Reagent (Sigma, St. Louis, MO, USA) according to the
manufacturer’s protocol. The isolated RNA (100 lg) was
subjected to puriﬁcation and mRNA selection using the
GenEluteTM mRNA Miniprep Kit (Sigma). First strand
cDNA was generated for 1 h at 37 C using Omniscript
reverse transcriptase (Qiagen, Hilden, Germany) primed with
a polyT25 primer. The cDNAs of interest were ampliﬁed
using speciﬁc primers and using the conditions listed in
Table 3. The resulting fragments were subcloned into pBlue-
scriptII SK+ (Stratagene, La Jolla, CA, USA) and sequenced
prior to transfer into pFastbac-FLAG vectors [27].
Expression of recombinant proteins
Recombinant baculoviruses containing the D. melanogaster
core-1 b3GalT candidate cDNAs were generated as des-
cribed previously [28]. After infection of 1.5 · 107
S. frugiperda Sf9 insect cells with recombinant baculoviruses
and incubation for 48 h at 27 C, the cells were washed in
50 mm Tris-buffered saline (TBS), pH 7.4 and lyzed in
500 lL TBS containing 2% (v ⁄ v) Triton X-100, 10 lgÆmL)1
benzamidine, 2 lgÆmL)1 pepstatin A, 2 lgÆmL)1 leupeptin,
2 lgÆmL)1 antipain, 2 lgÆmL)1 chymostatin and 0.2 mm
phenylmethanesulfonyl ﬂuoride (all from Fluka, Buchs,
Switzerland). Post-nuclear supernatants were diluted to 1%
(v ⁄ v) Triton X-100 in TBS and amounts of lysate corres-
ponding to 5 mg total proteins were incubated with 120 lL
EZviewTM Red Anti-FLAG-bead suspension (Sigma)
under rotation for 10 h at 4 C. Beads were washed
three times with 2 mL ice-cold TBS and diluted to 25 lg
total proteinÆlL)1 slurry. The integrity and amounts of
FLAG-tagged recombinant proteins were inspected by
western blotting.
Glycosyltransferase assays
Enzymatic activity towards p-nitrophenyl (pNP) and benzyl
(Bz) derivatized monosaccharide acceptors (Sigma) was
assayed using 250 lg bead-bound enzyme (10 lL) in 50 lL
100 mm cacodylate buffer pH 6.6, 20 mm MnCl2, 5% (v ⁄ v)
Me2SO, 0.4% (v ⁄ v) Triton X-100, 0.2 lgÆmL)1 3·FLAG
peptide (Sigma), 0.1 mm UDP-Gal (Fluka) including
2.5 · 104 c.p.m. UDP-[14C]Gal (Amersham Biosciences,
Arlington Heights, IL, USA), and 10 mm acceptor substrates
(Table 1). Galactosyltransferase activity with CG9520
towards GalNAc(a1-O)Bz and GlcNAc(a1-O)pNP were
measured with 0.5 mm UDP-Gal. Reactions were incubated
at 25 C for 10–30 min or overnight for acceptor screening,
then stopped by incubation at 72 C for 5 min. Reaction
products were puriﬁed over C18 Sep-Pak cartridges (Waters,
Milford, MA, USA) as described [28] and radioactivity was
quantiﬁed in a Tri-Carb 2900TR liquid scintillation counter
(Packard, Pangbourne, UK) with luminescence correction.
Assays towards MUC5AC derived glycopeptide acceptors [6]
Table 3. Primers and conditions for molecular cloning of D. melanogaster core-1 b3GalT homologs. Gene names are given according to Fly-
base (http://www.flybase.org) except for CG13904-1 (see main text). Restriction endonucleases used to clone PCR fragment into pBluescript
SK+ are given in parenthesis and the corresponding restriction sites are underlined.
Gene Annealing Temp (C) Fragment size (bp)
CG9520
Forward AAAACAAAAGCCAAATGACTGCCAAC (SmaI) 56.5 1188
Reverse TGTCTAGATTATTGCGTCTTTGTCTCGGC (XbaI)
CG8708
Forward AGGGATCCCACAATAAGTGCA GAATG (BamHI) 56 1434
Reverse GCGGTCTAGACTCAGAAACAG CTCAG (XbaI)
CG2975
Forward GGAATTCCCTCAAGAGGAGCATAGAATG (EcoRI) 55.5 1232
Reverse GCTCTAGAGCAGTCAATCCGAAATGAATG (XbaI)
CG13904-1
Forward AGCTGGATCCGGTTAGTTGCAG (BamHI)
Reverse TTGACTGTCGGTACCTTAAAATGAGTC (KpnI) 57.5 1123
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were carried out under similar conditions, except that the
reaction volume was reduced to 25 lL, Me2SO was omitted
and using 0.1 mm UDP-Gal together with 5 · 104 c.p.m.
UDP-[14C]galactose. The enzymatic reaction was stopped
by adding 500 lL cold H2O. Samples were loaded on an
AG1-X8 column (Bio-Rad, Hercules, CA, USA) and reac-
tion products were eluted with H2O. Assays towards the
glycoprotein acceptors asialo-bovine submaxillary mucin
(Sigma) and asialo-ovine submaxillary mucin (kindly provi-
ded by R.L. Hill, Duke University Medical Center, Durham,
NC, USA) were carried out as described above for monosac-
charide acceptor-based assays. Reaction products were preci-
pitated with 1 mL cold 15% (v ⁄ v) trichloroacetic acid, 5%
(v ⁄ v) phosphotungstic acid in H2O, spotted on glass ﬁber
ﬁlters (Whatman, Maidstone, UK) as described elsewhere
[29] and measured in a scintillation b-counter.
Structural analysis
Dried mixtures containing GalNAc(a1-O)Bz and the prod-
uct of the reaction with the galactosyltransferases studied
were taken up in 80% (v ⁄ v) acetonitrile in water and subjec-
ted to normal phase HPLC on a TSKgel Amide-80 column
(4.6 · 250 mm, Tosoh Bioscience, Montgomeryville, PA,
USA) at a ﬂow rate of 1 mLÆmin)1. Solvent A was 50 mm
ammonium formate at pH 4.4 and solvent B was 95% (v ⁄ v)
acetonitrile. The column was equilibrated with 80% solvent
B. After a 1-min hold postinjection the percentage of sol-
vent B was lowered to 73%. Bz-glycosides were monitored
at 254 nm. Peaks were examined by direct infusion electro-
spray-MS on a Q-Tof Global (Waters). Bz-disaccharide
containing fractions were dried and permethylated using
solid NaOH [30]. Partially permethylated alditol acetates
were prepared using NaBD4 as the reducing agent and ana-
lyzed by GC-MS using a 30 m ⁄ 0.25 mm ⁄ 0.25 lm HP5 col-
umn (Agilent, Palo Alto, CA, USA) and an Agilent GC-MS
apparatus with helium as the carrier gas. Samples were
injected with a low split at an oven temperature of 140 C
which was raised to 190 C and to 260 C with 10 and
4 CÆmin)1, respectively.
TLC
Glycolipids were extracted from D. melanogaster Schneider-
S2 cells and 15 lg of mannose equivalents were used per
glycosyltransferase assay as described previously [27] except
that Triton X-100 was added to 1.4%. For TLC analysis,
reaction products were dried under N2, taken up in 100 lL
H2O and extracted 10 times with 900 lL toluene to remove
Triton X-100 from the samples. Glycolipids were developed
in chloroform ⁄methanol ⁄ 0.25% aqueous potassium chlor-
ide (10 : 10 : 3; v ⁄ v ⁄ v) on silica gel 60 aluminium high-
performance TLC plates (Merck, Darmstadt, Germany).
Plates were stained with orcinol sulfuric acid (Sigma) and
autoradiographed for 24 h.
HPLC analysis
[14C]Gal-labeled Schneider-S2 glycolipids (30 lg mannose
equivalents) were developed by TLC and autoradiographed
as outlined above. Radioactive bands were excised from
the TLC plate and glycolipids were extracted from the
silica matrix by sonication in methanol. Samples were sub-
jected to mild acid hydrolysis in 40 mm triﬂuoroacetic acid
in methanol ⁄H2O (1 ⁄ 1; v ⁄ v) for 10 min at 100 C to elimi-
nate acid labile glycan modiﬁcations [31], dried under N2,
taken up in 200 lL 50 mm sodium acetate pH 5.0,
0.75 mgÆmL)1 sodium cholate (Sigma) prior to the addition
of 0.2 U ceramide glycanase (Dextra Laboratory Ltd,
Reading, UK) for a 24-h incubation at 37 C, which was
repeated for another 24 h. Reactions were stopped by
extracting three times with 400 lL of H2O-saturated buta-
nol. The aqueous phase was dried brieﬂy to remove resid-
ual butanol, subjected to a C18 Sep-Pak cartridge and
ENVI-Carb column puriﬁcation, 2AB derivatization and
paper disk clean up as described [32] with minor modiﬁca-
tions. Notably, samples were eluted from the ENVI-Carb
column with 4 mL 50% (v ⁄ v) acetonitrile, subjected to
2AB-labeling and subsequent paper-disk clean up by placing
the paper disk into 0.5 mL Ultrafree-MC ﬁlter devices
(Millipore, Bedford, MA, USA). 2AB-labelled saccharides
were eluted three times with 50 lL H2O and aliquots were
analyzed by GlycoSep–N normal phase chromatography
[32] coupled to a Packard 500TR Series ﬂow scintillation
detector. Alternatively, 400-lL fractions were collected
and radioactivity of each fraction was quantiﬁed with a
Tri-Carb 2900TR liquid scintillation counter (Packard).
In situ hybridization
DIG-labeled RNA probes were prepared using the DIG
RNA labeling Kit (Roche, Branchberg, NJ) by in vitro
transcription with T7, T3 or SP6 RNA polymerase using
pBluescript II SK+ (Stratagene) or pGEM (Promega,
Madison, WI, USA) derived DNA templates. Control reac-
tions were carried out with sense transcripts. The probes,
approximately 1 kb, were hydrolyzed for 90 min using
standard procedures, precipitated with LiCl2 and ethanol
and quantiﬁed relative to each other following a protocol
from the Berkley Drosophila Genome Project (BDGP) avail-
able at (http://www.bdgp.org/about/methods/Quantiﬁcation_
of_RNA.html). Equal amounts of DIG-labeled transcripts
were used to probe 0–22-h-old y1w1 embryos following the
method of Tautz and Pfeiﬂe [33].
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Conclusion and Outlook*
The determination of glycan structures and enzymological parameters of GTs remain essential 
tasks, but a systemic view on the function of the individual glycan is desirable. Therefore, the 
use of GT mutant alleles in the genetic analysis of glycan functions represents a step towards a 
better understanding of glycans. If no mutant for a GT locus is available, targeted overexpression 
(189), targeted disruption (190) or RNA interference mediated knock-down (191, 192) can be 
used to generate misexpressor lines, knock-out lines or phenocopies of null mutations. Structural 
differences between glycoconjugates from mutants and wild-type flies (98) also constitute the 
most convincing proof for the non-redundancy of an enzyme and the specificity for the glycan-
biosynthetic pathway deduced from in vitro assays.  
Along this line, it is largely unknown how the different glycosylation pathways are separated. 
For example, the linkage region of proteoglycans (Figure 13) displays the same terminal sequon 
as the Az sub-series of GSLs (Figure 15), GlcAE1,3GalE. However, GSLs do not seem to be a 
substrate for the highly processive GAG biosynthetic machinery in vivo, since no GlcA 
containing glycolipid has been found in dipterans which is elongated any further (82, 128, 193). 
Mechanisms for glycan-type separation have been exemplified in mammalian GSL biosynthesis: 
In some cells, lactosylceramide (GalE1,4GlcECer, c.f. Figure 16) synthase and the enzyme 
forming sialosyllactosylceramide were shown to form a complex (194), committing this GSL-
species to the ganglioside pathway by the formation of a GT-complex. In other cells, 
lactosylceramide has been demonstrated to be sandwiched by a “glycolipid transfer protein” 
(195), committing it to the lacto-series pathway by a possible substrate protection mechanism. 
Genetic screens in D. melanogaster may also reveal genes responsible for the separation of 
individual glycan biosynthetic pathways. 
To identify genes involved in glycan biosynthesis without prior knowledge of their sequence, a 
selection strategy involving toxic lectins as described with C. elegans (196, [II]) could be 
employed. For example, mutagenized D. melanogaster larvae would be fed specific Bacillus 
thuringiensis strains or toxins from other endospore forming bacilli. These toxins are used to 
control secondary pests of D. melanogaster in the vineyards of the Middle East (197). Some 
toxins that are active against D. melanogaster, encompassing the Cry4 -(crystal toxin 4) family 
(personal communication Dr. Hala Khyami-Horani), display a lectin-like domain (198), 
indicating that they might require glycan binding for toxicity similarly to Cry14A or Cry5B in C.
elegans [II]. While such selection strategies can limit time and expenses necessary to find 
* Citations refer to section 11 of the introductory text to this thesis („Literature cited“) 
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carbohydrate active enzymes expressed in the gut, visual inspection of phenotypes will still be 
required to score interactions of glycans in D. melanogaster. Genetic interaction experiments 
using GT loci allow addressing questions like: Which glycan interacts with which lectin? Which 
glycoconjugates require the glycan for function and which ones do not? Which signalling 
pathways are affected and at which level?  
Since screening for interactors of GTs will represent a major organisational and technical 
challenge, one could resort to computational methods to identify a subset of candidate 
glycoconjugates and cross available mutants to GT alleles. Taking core1 bearing proteins (Figure 
19) as an example, neural network predictions could be used to look for O-GalNAc sites in a 
given amino acid sequence. At the moment, 76% of mammalian ppGalNAcT- substrates are 
correctly predicted (199). Furthermore, a metabolic labelling approach using the GalNAc 
analogue N-azidoacetylgalactosamine (GalNAz) was developed (200), eventually allowing large 
scale identification of mucin type O-glycosylated proteins in cell lines. On the other hand, lectins 
and other interactors will still have to be identified by screens, although biochemical methods as 
the use of glycan- arrays or –columns, and computational methods as sequence similarity 
searches with sequences of known lectins might identify candidates for glycan- binding proteins. 
The genetic analysis of GT alleles is not without pitfalls and might, as in the case of HSPGs, 
display a plethora of interactions, which are difficult to disentangle because of interacting 
signalling pathways (discussed in ref. 201). Furthermore, GSLs have both the capability to bind 
lectins (16) and are structural components of D. melanogaster rafts (202). Rafts are two 
dimensional microdomains on membranes, which influence many different receptor ligand 
interactions (reviewed in ref. 203). For example, EGFR activation in mammals occurs upon 
removal of cholesterol from membranes (204), a method which destroys rafts. It may therefore 
be difficult to separate GSL-lectin interactions and raft-preserving functions of GSLs, a problem 
that also arises in the interpretation of the brainiac phenotype and may partially explain 
pleiotropic interactions. The case of fringe, which seems to primarily affect one receptor, may 
well be the exception. To circumvent these problems, it appears imperative to find the most 
isolated system to study mutant allele interactions, where the genetic information can be 
interpreted against the available background of biochemical data. 
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